Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyZiprasidone
Identification
- Name
- Ziprasidone
- Accession Number
- DB00246 (APRD00540)
- Type
- Small Molecule
- Groups
- Approved
- Description
Ziprasidone (marketed as Geodon, Zeldox) was the fifth atypical antipsychotic to gain FDA approval (February 2001). Ziprasidone is Food and Drug Administration (FDA) approved for the treatment of schizophrenia, and the intramuscular injection form of ziprasidone is approved for acute agitation in schizophrenic patients. Ziprasidone has also received approval for acute treatment of mania associated with bipolar disorder. [Wikipedia]
- Structure
Structure for DB00246 (Ziprasidone)
- Synonyms
- Ziprasidona
- Ziprasidone
- Ziprasidonum
- Product Ingredients
Ingredient UNII CAS InChI Key Ziprasidone hydrochloride JAL53626GG 122883-93-6 NZDBKBRIBJLNNT-UHFFFAOYSA-N Ziprasidone mesylate trihydrate 3X6SAX83JZ 199191-69-0 WLQZEFFFIUHSJB-UHFFFAOYSA-N - Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Geodon Capsule 40 mg/1 Oral Remedy Repack 2010-12-20 2017-06-21 US 
Geodon Capsule 80 mg/1 Oral Roerig 2013-11-01 Not applicable US Geodon Capsule 40 mg/1 Oral State of Florida DOH Central Pharmacy 2009-07-01 Not applicable US Geodon Capsule 40 mg/1 Oral Rebel Distributors 2001-02-05 Not applicable US 
Geodon Injection, powder, lyophilized, for solution 20 mg/mL Intramuscular Cardinal Health 2003-12-23 2017-12-22 US Geodon Capsule 80 mg/1 Oral Roerig 2001-02-05 Not applicable US Geodon Capsule 20 mg/1 Oral Lake Erie Medical Dba Quality Care Produts Llc 2010-11-05 2018-05-11 US Geodon Capsule 80 mg/1 Oral Rebel Distributors 2001-02-05 Not applicable US Geodon Capsule 60 mg/1 Oral Cardinal Health 2001-02-05 2017-12-22 US Geodon Capsule 20 mg/1 Oral Remedy Repack 2010-12-20 2018-04-07 US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Auro-ziprasidone Capsule 40 mg Oral Auro Pharma Inc 2018-03-19 Not applicable Canada 
Auro-ziprasidone Capsule 80 mg Oral Auro Pharma Inc 2018-03-19 Not applicable Canada Auro-ziprasidone Capsule 20 mg Oral Auro Pharma Inc 2018-03-19 Not applicable Canada Auro-ziprasidone Capsule 60 mg Oral Auro Pharma Inc 2018-03-19 Not applicable Canada Gd-ziprasidone Capsule 40 mg Oral Genmed A Division Of Pfizer Canada Inc Not applicable Not applicable Canada Gd-ziprasidone Capsule 80 mg Oral Genmed A Division Of Pfizer Canada Inc Not applicable Not applicable Canada Gd-ziprasidone Capsule 20 mg Oral Genmed A Division Of Pfizer Canada Inc Not applicable Not applicable Canada Gd-ziprasidone Capsule 60 mg Oral Genmed A Division Of Pfizer Canada Inc Not applicable Not applicable Canada Mylan-ziprasidone Capsule 20 mg Oral Mylan Pharmaceuticals Not applicable Not applicable Canada Mylan-ziprasidone Capsule 60 mg Oral Mylan Pharmaceuticals Not applicable Not applicable Canada - Categories
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-2 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Adrenergic Antagonists
- Anticholinergic Agents
- Antiemetics Antagonists
- Antipsychotic Agents
- Antipsychotic Agents (Second Generation [Atypical])
- Central Nervous System Agents
- Central Nervous System Depressants
- Cytochrome P-450 CYP1A2 Substrates
- Cytochrome P-450 CYP2D6 Inhibitors
- Cytochrome P-450 CYP2D6 Inhibitors (weak)
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors (moderate)
- Cytochrome P-450 Enzyme Inhibitors
- Dopamine Agents
- Dopamine Antagonists
- Dopamine D2 Receptor Antagonists
- Highest Risk QTc-Prolonging Agents
- Histamine Antagonists
- Histamine H1 Antagonists
- Hyperglycemia-Associated Agents
- Indole Derivatives
- Muscarinic Antagonists
- Nervous System
- Neurotransmitter Agents
- Psycholeptics
- Psychotropic Drugs
- QTc Prolonging Agents
- Serotonin 5-HT1 Receptor Agonists
- Serotonin 5-HT1 Receptor Antagonists
- Serotonin 5-HT2 Receptor Antagonists
- Serotonin Agents
- Serotonin Receptor Agonists
- Serotonin Receptor Antagonists
- Sulfur Compounds
- Tranquilizing Agents
- UNII
- 6UKA5VEJ6X
- CAS number
- 146939-27-7
- Weight
- Average: 412.936
Monoisotopic: 412.112459711 - Chemical Formula
- C21H21ClN4OS
- InChI Key
- MVWVFYHBGMAFLY-UHFFFAOYSA-N
- InChI
- InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27)
- IUPAC Name
- 5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-2,3-dihydro-1H-indol-2-one
- SMILES
- ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1
Pharmacology
- Indication
For the treatment of schizophrenia and related psychotic disorders.
- Associated Conditions
- Pharmacodynamics
Ziprasidone is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Ziprasidone is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors. Ziprasidone acts as an antagonist at other receptors, but with lower potency. Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other therapeutic and side effects of Ziprasidone. Ziprasidone's antagonism of muscarinic M1-5 receptors may explain its anticholinergic effects. Ziprasidone's antagonism of histamine H1 receptors may explain the somnolence observed with this drug. Ziprasidone's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug. Ziprasidone functions as an antagonist at the Dopamine D2 , 5HT-2A , and 5HT-1D receptors, and as an agonist at the 5HT-1A receptor. Ziprasidone also inhibits synaptic reuptake of serotonin and norepinephrine.
- Mechanism of action
Ziprasidone's antipsychotic activity is likely due to a combination of its antagonistic function at D2 receptors in the mesolimbic pathways and at 5HT2A receptors in the frontal cortex. Alleviation of positive symptoms is due to antagonism at D2 receptors while relief of negative symptoms are due to 5HT2A antagonism.
- Absorption
~60%
- Volume of distribution
- 1.5 L/kg
- Protein binding
99%
- Metabolism
Hepatic
- Route of elimination
Ziprasidone is extensively metabolized after oral administration with only a small amount excreted in the urine (<1%) or feces (<4%) as unchanged drug. Approximately 20% of the dose is excreted in the urine, with approximately 66% being eliminated in the feces.
- Half life
7 hours
- Clearance
- 7.5 mL/min/kg
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE The therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Ziprasidone. Experimental 2,4-thiazolidinedione The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Ziprasidone. Investigational 2,5-Dimethoxy-4-ethylamphetamine Ziprasidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine. Experimental, Illicit 2,5-Dimethoxy-4-ethylthioamphetamine Ziprasidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine. Experimental 3,4-Methylenedioxyamphetamine Ziprasidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine. Experimental, Illicit 4-Bromo-2,5-dimethoxyamphetamine Ziprasidone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine. Experimental, Illicit 4-Methoxyamphetamine The metabolism of 4-Methoxyamphetamine can be decreased when combined with Ziprasidone. Experimental, Illicit 7-Nitroindazole The risk or severity of adverse effects can be increased when Ziprasidone is combined with 7-Nitroindazole. Experimental 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline The metabolism of Ziprasidone can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline. Experimental Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Ziprasidone. Approved, Investigational Abiraterone The serum concentration of Ziprasidone can be increased when it is combined with Abiraterone. Approved Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Ziprasidone. Approved, Investigational Acebutolol Acebutolol may increase the orthostatic hypotensive activities of Ziprasidone. Approved, Investigational Acenocoumarol The metabolism of Acenocoumarol can be decreased when combined with Ziprasidone. Approved, Investigational Acepromazine Ziprasidone may increase the antihypertensive activities of Acepromazine. Approved, Vet Approved Aceprometazine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Aceprometazine. Approved Acetaminophen The metabolism of Acetaminophen can be decreased when combined with Ziprasidone. Approved Acetohexamide The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Ziprasidone. Approved, Investigational, Withdrawn Acetyl sulfisoxazole The metabolism of Ziprasidone can be decreased when combined with Acetyl sulfisoxazole. Approved, Vet Approved Acetylcholine The metabolism of Acetylcholine can be decreased when combined with Ziprasidone. Approved Adinazolam The metabolism of Adinazolam can be decreased when combined with Ziprasidone. Approved Adipiplon The risk or severity of adverse effects can be increased when Ziprasidone is combined with Adipiplon. Investigational Adrafinil Ziprasidone may decrease the vasoconstricting activities of Adrafinil. Withdrawn Agmatine Ziprasidone may decrease the vasoconstricting activities of Agmatine. Experimental, Investigational Agomelatine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Agomelatine. Approved, Investigational AICA ribonucleotide The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Ziprasidone. Experimental, Investigational Ajmaline The metabolism of Ajmaline can be decreased when combined with Ziprasidone. Approved, Investigational Alaproclate The risk or severity of adverse effects can be increased when Ziprasidone is combined with Alaproclate. Experimental Albendazole The metabolism of Albendazole can be decreased when combined with Ziprasidone. Approved, Vet Approved Alclometasone The metabolism of Alclometasone can be decreased when combined with Ziprasidone. Approved Alfaxalone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Alfaxalone. Vet Approved Alfentanil The metabolism of Alfentanil can be decreased when combined with Ziprasidone. Approved, Illicit Alfuzosin Alfuzosin may increase the antihypertensive activities of Ziprasidone. Approved, Investigational Aliskiren The metabolism of Aliskiren can be decreased when combined with Ziprasidone. Approved, Investigational Allicin The therapeutic efficacy of Allicin can be decreased when used in combination with Ziprasidone. Investigational Allopregnanolone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Allopregnanolone. Investigational Allylestrenol The metabolism of Allylestrenol can be decreased when combined with Ziprasidone. Approved Almotriptan The metabolism of Almotriptan can be decreased when combined with Ziprasidone. Approved, Investigational Alogliptin The metabolism of Alogliptin can be decreased when combined with Ziprasidone. Approved Alosetron The metabolism of Alosetron can be decreased when combined with Ziprasidone. Approved, Withdrawn alpha-Tocopherol acetate The metabolism of alpha-Tocopherol acetate can be decreased when combined with Ziprasidone. Approved Alphacetylmethadol The risk or severity of adverse effects can be increased when Ziprasidone is combined with Alphacetylmethadol. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Alphaprodine. Illicit Alprazolam The metabolism of Alprazolam can be decreased when combined with Ziprasidone. Approved, Illicit, Investigational Alprenolol Alprenolol may increase the orthostatic hypotensive activities of Ziprasidone. Approved, Withdrawn Amantadine The therapeutic efficacy of Amantadine can be decreased when used in combination with Ziprasidone. Approved Ambrisentan The metabolism of Ambrisentan can be decreased when combined with Ziprasidone. Approved, Investigational Ambroxol The metabolism of Ambroxol can be decreased when combined with Ziprasidone. Approved, Investigational Amibegron Ziprasidone may decrease the vasoconstricting activities of Amibegron. Investigational Aminophenazone The metabolism of Aminophenazone can be decreased when combined with Ziprasidone. Approved, Withdrawn Aminophylline The metabolism of Aminophylline can be decreased when combined with Ziprasidone. Approved Amiodarone The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Amiodarone. Approved, Investigational Amisulpride Ziprasidone may increase the antipsychotic activities of Amisulpride. Approved, Investigational Amitraz Ziprasidone may decrease the vasoconstricting activities of Amitraz. Vet Approved Amitriptyline Ziprasidone may increase the antihypertensive activities of Amitriptyline. Approved Amlodipine The metabolism of Amlodipine can be decreased when combined with Ziprasidone. Approved Amobarbital The risk or severity of adverse effects can be increased when Ziprasidone is combined with Amobarbital. Approved, Illicit Amoxapine Ziprasidone may increase the antihypertensive activities of Amoxapine. Approved Amperozide The risk or severity of adverse effects can be increased when Ziprasidone is combined with Amperozide. Experimental Amphetamine The metabolism of Ziprasidone can be decreased when combined with Amphetamine. Approved, Illicit, Investigational Amprenavir The metabolism of Amprenavir can be decreased when combined with Ziprasidone. Approved, Investigational Amrinone The risk or severity of hypotension can be increased when Ziprasidone is combined with Amrinone. Approved Amsacrine The metabolism of Amsacrine can be decreased when combined with Ziprasidone. Approved, Investigational Anagrelide The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Anagrelide. Approved Anisodamine Ziprasidone may decrease the vasoconstricting activities of Anisodamine. Investigational Antipyrine The metabolism of Antipyrine can be decreased when combined with Ziprasidone. Approved, Investigational Apalutamide The serum concentration of Ziprasidone can be decreased when it is combined with Apalutamide. Approved, Investigational Apixaban The serum concentration of Apixaban can be increased when it is combined with Ziprasidone. Approved Apomorphine The therapeutic efficacy of Apomorphine can be decreased when used in combination with Ziprasidone. Approved, Investigational Apraclonidine Ziprasidone may decrease the vasoconstricting activities of Apraclonidine. Approved Apremilast The metabolism of Apremilast can be decreased when combined with Ziprasidone. Approved, Investigational Aprepitant The serum concentration of Ziprasidone can be increased when it is combined with Aprepitant. Approved, Investigational Aprindine The metabolism of Aprindine can be decreased when combined with Ziprasidone. Approved Aranidipine The risk or severity of hypotension can be increased when Ziprasidone is combined with Aranidipine. Approved, Investigational Arbutamine Ziprasidone may decrease the vasoconstricting activities of Arbutamine. Approved Arformoterol Arformoterol may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Argatroban The metabolism of Argatroban can be decreased when combined with Ziprasidone. Approved, Investigational Aripiprazole The serum concentration of Aripiprazole can be increased when it is combined with Ziprasidone. Approved, Investigational Arotinolol Arotinolol may increase the orthostatic hypotensive activities of Ziprasidone. Investigational Arsenic trioxide The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Arsenic trioxide. Approved, Investigational Artemether The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Artemether. Approved Articaine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Articaine. Approved Asenapine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Asenapine. Approved Astemizole The metabolism of Astemizole can be decreased when combined with Ziprasidone. Approved, Withdrawn Asunaprevir The serum concentration of Asunaprevir can be increased when it is combined with Ziprasidone. Approved, Investigational, Withdrawn Atazanavir The metabolism of Ziprasidone can be decreased when combined with Atazanavir. Approved, Investigational Atenolol Atenolol may increase the orthostatic hypotensive activities of Ziprasidone. Approved Atomoxetine Atomoxetine may increase the QTc-prolonging activities of Ziprasidone. Approved Atorvastatin The risk or severity of adverse effects can be increased when Ziprasidone is combined with Atorvastatin. Approved Avanafil The serum concentration of Avanafil can be increased when it is combined with Ziprasidone. Approved Avatrombopag The metabolism of Avatrombopag can be decreased when combined with Ziprasidone. Approved, Investigational Axitinib The metabolism of Axitinib can be decreased when combined with Ziprasidone. Approved, Investigational Azaperone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Azaperone. Investigational, Vet Approved Azelastine Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Azelnidipine The risk or severity of hypotension can be increased when Ziprasidone is combined with Azelnidipine. Approved, Investigational Azimilide The risk or severity of hypotension can be increased when Ziprasidone is combined with Azimilide. Investigational Azithromycin Azithromycin may increase the QTc-prolonging activities of Ziprasidone. Approved Baclofen The risk or severity of adverse effects can be increased when Ziprasidone is combined with Baclofen. Approved Balaglitazone The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Ziprasidone. Investigational Bambuterol Ziprasidone may decrease the vasoconstricting activities of Bambuterol. Approved, Investigational Banoxantrone The metabolism of Banoxantrone can be decreased when combined with Ziprasidone. Investigational Barbital The risk or severity of adverse effects can be increased when Ziprasidone is combined with Barbital. Illicit Baricitinib The metabolism of Baricitinib can be decreased when combined with Ziprasidone. Approved, Investigational Barnidipine The risk or severity of hypotension can be increased when Ziprasidone is combined with Barnidipine. Approved Bedaquiline Bedaquiline may increase the QTc-prolonging activities of Ziprasidone. Approved Befunolol Befunolol may increase the orthostatic hypotensive activities of Ziprasidone. Experimental Bempedoic acid The therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Ziprasidone. Investigational Bencyclane The risk or severity of hypotension can be increased when Ziprasidone is combined with Bencyclane. Experimental Benidipine The metabolism of Benidipine can be decreased when combined with Ziprasidone. Approved, Investigational Benmoxin The metabolism of Ziprasidone can be decreased when combined with Benmoxin. Withdrawn Benperidol The risk or severity of adverse effects can be increased when Ziprasidone is combined with Benperidol. Approved, Investigational Benzatropine The metabolism of Benzatropine can be decreased when combined with Ziprasidone. Approved Benzocaine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Benzocaine. Approved, Investigational Benzphetamine The metabolism of Benzphetamine can be decreased when combined with Ziprasidone. Approved, Illicit Benzyl alcohol The metabolism of Benzyl alcohol can be decreased when combined with Ziprasidone. Approved Benzylpenicilloyl Polylysine Ziprasidone may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent. Approved Bepridil The metabolism of Bepridil can be decreased when combined with Ziprasidone. Approved, Withdrawn Betahistine The therapeutic efficacy of Betahistine can be decreased when used in combination with Ziprasidone. Approved, Investigational Betaxolol Betaxolol may increase the orthostatic hypotensive activities of Ziprasidone. Approved, Investigational Bevantolol Ziprasidone may increase the antihypertensive activities of Bevantolol. Approved Bexarotene The metabolism of Bexarotene can be decreased when combined with Ziprasidone. Approved, Investigational Bezafibrate The metabolism of Bezafibrate can be decreased when combined with Ziprasidone. Approved, Investigational Bicalutamide The metabolism of Bicalutamide can be decreased when combined with Ziprasidone. Approved Bictegravir The metabolism of Bictegravir can be decreased when combined with Ziprasidone. Approved, Investigational Bioallethrin The metabolism of Bioallethrin can be decreased when combined with Ziprasidone. Approved, Experimental Bisoprolol Bisoprolol may increase the orthostatic hypotensive activities of Ziprasidone. Approved Bitolterol Ziprasidone may decrease the vasoconstricting activities of Bitolterol. Withdrawn Blonanserin The metabolism of Blonanserin can be decreased when combined with Ziprasidone. Approved, Investigational Boceprevir The metabolism of Ziprasidone can be decreased when combined with Boceprevir. Approved, Withdrawn Bopindolol Bopindolol may increase the orthostatic hypotensive activities of Ziprasidone. Approved Bortezomib Bortezomib may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Bosentan The serum concentration of Bosentan can be increased when it is combined with Ziprasidone. Approved, Investigational Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Ziprasidone. Approved Brentuximab vedotin The metabolism of Brentuximab vedotin can be decreased when combined with Ziprasidone. Approved, Investigational Brexpiprazole The serum concentration of Brexpiprazole can be increased when it is combined with Ziprasidone. Approved, Investigational Brigatinib The metabolism of Brigatinib can be decreased when combined with Ziprasidone. Approved, Investigational Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone. Approved Brinzolamide The metabolism of Brinzolamide can be decreased when combined with Ziprasidone. Approved Brivaracetam The metabolism of Brivaracetam can be decreased when combined with Ziprasidone. Approved, Investigational Brofaromine The metabolism of Ziprasidone can be decreased when combined with Brofaromine. Experimental Bromazepam The metabolism of Bromazepam can be decreased when combined with Ziprasidone. Approved, Illicit, Investigational Bromisoval The risk or severity of adverse effects can be increased when Ziprasidone is combined with Bromisoval. Experimental Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Ziprasidone. Approved, Investigational Bromperidol The risk or severity of adverse effects can be increased when Ziprasidone is combined with Bromperidol. Approved, Investigational Brompheniramine The metabolism of Brompheniramine can be decreased when combined with Ziprasidone. Approved Brotizolam The risk or severity of adverse effects can be increased when Ziprasidone is combined with Brotizolam. Approved, Investigational, Withdrawn Bucindolol Bucindolol may increase the antihypertensive activities of Ziprasidone. Investigational Budesonide The serum concentration of Budesonide can be increased when it is combined with Ziprasidone. Approved Buformin The therapeutic efficacy of Buformin can be decreased when used in combination with Ziprasidone. Investigational, Withdrawn Bufuralol Bufuralol may increase the orthostatic hypotensive activities of Ziprasidone. Experimental, Investigational Bunazosin Bunazosin may increase the antihypertensive activities of Ziprasidone. Investigational Bupivacaine The metabolism of Bupivacaine can be decreased when combined with Ziprasidone. Approved, Investigational Bupranolol Bupranolol may increase the orthostatic hypotensive activities of Ziprasidone. Approved Buprenorphine Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Bupropion The metabolism of Bupropion can be decreased when combined with Ziprasidone. Approved Buserelin Buserelin may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Buspirone The metabolism of Buspirone can be decreased when combined with Ziprasidone. Approved, Investigational Busulfan The metabolism of Busulfan can be decreased when combined with Ziprasidone. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Ziprasidone. Approved, Illicit Butacaine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Butacaine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Ziprasidone is combined with Butalbital. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Ziprasidone is combined with Butamben. Approved, Withdrawn Butethal The risk or severity of adverse effects can be increased when Ziprasidone is combined with Butethal. Approved, Illicit Butorphanol The risk or severity of adverse effects can be increased when Ziprasidone is combined with Butorphanol. Approved, Illicit, Vet Approved Cabazitaxel The metabolism of Cabazitaxel can be decreased when combined with Ziprasidone. Approved Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Ziprasidone. Approved Cabozantinib The metabolism of Cabozantinib can be decreased when combined with Ziprasidone. Approved, Investigational Caffeine The metabolism of Caffeine can be decreased when combined with Ziprasidone. Approved Calcitriol The metabolism of Calcitriol can be decreased when combined with Ziprasidone. Approved, Nutraceutical Canagliflozin The metabolism of Canagliflozin can be decreased when combined with Ziprasidone. Approved Canertinib The risk or severity of adverse effects can be increased when Ziprasidone is combined with Canertinib. Investigational Cannabidiol The metabolism of Cannabidiol can be decreased when combined with Ziprasidone. Approved, Investigational Captopril The metabolism of Captopril can be decreased when combined with Ziprasidone. Approved Carbamazepine The serum concentration of Ziprasidone can be decreased when it is combined with Carbamazepine. Approved, Investigational Carbinoxamine The metabolism of Carbinoxamine can be decreased when combined with Ziprasidone. Approved Carboxyamidotriazole The risk or severity of hypotension can be increased when Ziprasidone is combined with Carboxyamidotriazole. Investigational Carbutamide The therapeutic efficacy of Carbutamide can be decreased when used in combination with Ziprasidone. Experimental Carfentanil The risk or severity of adverse effects can be increased when Ziprasidone is combined with Carfentanil. Illicit, Investigational, Vet Approved Cariprazine The metabolism of Cariprazine can be decreased when combined with Ziprasidone. Approved, Investigational Carisoprodol The risk or severity of adverse effects can be increased when Ziprasidone is combined with Carisoprodol. Approved Caroverine The risk or severity of hypotension can be increased when Ziprasidone is combined with Caroverine. Experimental Caroxazone The metabolism of Ziprasidone can be decreased when combined with Caroxazone. Withdrawn Carteolol Carteolol may increase the orthostatic hypotensive activities of Ziprasidone. Approved Carvedilol Carvedilol may increase the antihypertensive activities of Ziprasidone. Approved, Investigational Castanospermine The therapeutic efficacy of Castanospermine can be decreased when used in combination with Ziprasidone. Experimental Celecoxib The metabolism of Celecoxib can be decreased when combined with Ziprasidone. Approved, Investigational Celiprolol Celiprolol may increase the orthostatic hypotensive activities of Ziprasidone. Approved, Investigational Cephalexin The metabolism of Cephalexin can be decreased when combined with Ziprasidone. Approved, Investigational, Vet Approved Ceritinib The serum concentration of Ziprasidone can be increased when it is combined with Ceritinib. Approved Cerivastatin The serum concentration of Cerivastatin can be increased when it is combined with Ziprasidone. Approved, Withdrawn Cetirizine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Cetirizine. Approved Cevimeline The metabolism of Cevimeline can be decreased when combined with Ziprasidone. Approved Chenodeoxycholic acid The metabolism of Chenodeoxycholic acid can be decreased when combined with Ziprasidone. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Ziprasidone is combined with Chloral hydrate. Approved, Illicit, Investigational, Vet Approved Chlordiazepoxide The metabolism of Chlordiazepoxide can be decreased when combined with Ziprasidone. Approved, Illicit, Investigational Chlormezanone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Chlormezanone. Approved, Investigational, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Chloroprocaine. Approved Chloroquine Chloroquine may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational, Vet Approved Chlorphenamine The metabolism of Chlorphenamine can be decreased when combined with Ziprasidone. Approved Chlorphentermine Ziprasidone may decrease the stimulatory activities of Chlorphentermine. Illicit, Withdrawn Chlorpromazine Chlorpromazine may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational, Vet Approved Chlorpropamide The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Ziprasidone. Approved, Investigational Chlorprothixene The risk or severity of adverse effects can be increased when Ziprasidone is combined with Chlorprothixene. Approved, Investigational, Withdrawn Chlorzoxazone The metabolism of Chlorzoxazone can be decreased when combined with Ziprasidone. Approved Cholecalciferol The metabolism of Cholecalciferol can be decreased when combined with Ziprasidone. Approved, Nutraceutical Ciclesonide The metabolism of Ciclesonide can be decreased when combined with Ziprasidone. Approved, Investigational Ciglitazone The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Ziprasidone. Experimental Cilnidipine The risk or severity of hypotension can be increased when Ziprasidone is combined with Cilnidipine. Approved, Investigational Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Ziprasidone. Approved, Investigational Cinacalcet The metabolism of Cinacalcet can be decreased when combined with Ziprasidone. Approved Cinchocaine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Cinchocaine. Approved, Vet Approved Cinnarizine The metabolism of Cinnarizine can be decreased when combined with Ziprasidone. Approved, Investigational Ciprofloxacin Ciprofloxacin may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Cirazoline Ziprasidone may decrease the vasoconstricting activities of Cirazoline. Experimental Cisapride The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Cisapride. Approved, Investigational, Withdrawn Citalopram The risk or severity of QTc prolongation can be increased when Citalopram is combined with Ziprasidone. Approved Clarithromycin Clarithromycin may increase the QTc-prolonging activities of Ziprasidone. Approved Clemastine The metabolism of Ziprasidone can be decreased when combined with Clemastine. Approved, Investigational Clenbuterol Ziprasidone may decrease the vasoconstricting activities of Clenbuterol. Approved, Investigational, Vet Approved Clevidipine The metabolism of Clevidipine can be decreased when combined with Ziprasidone. Approved, Investigational Clidinium The risk or severity of adverse effects can be increased when Ziprasidone is combined with Clidinium. Approved Clindamycin The metabolism of Clindamycin can be decreased when combined with Ziprasidone. Approved, Vet Approved Clobazam The metabolism of Clobazam can be decreased when combined with Ziprasidone. Approved, Illicit Clofazimine The metabolism of Clofazimine can be decreased when combined with Ziprasidone. Approved, Investigational Clofibrate The metabolism of Clofibrate can be decreased when combined with Ziprasidone. Approved, Investigational clomethiazole The metabolism of clomethiazole can be decreased when combined with Ziprasidone. Investigational Clomipramine Clomipramine may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational, Vet Approved Clonazepam The metabolism of Clonazepam can be decreased when combined with Ziprasidone. Approved, Illicit Clonidine The metabolism of Clonidine can be decreased when combined with Ziprasidone. Approved Clopenthixol The risk or severity of adverse effects can be increased when Ziprasidone is combined with Clopenthixol. Experimental Clopidogrel The metabolism of Clopidogrel can be decreased when combined with Ziprasidone. Approved Cloranolol Cloranolol may increase the orthostatic hypotensive activities of Ziprasidone. Experimental Clorazepate The metabolism of Clorazepate can be decreased when combined with Ziprasidone. Approved, Illicit Clothiapine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Clothiapine. Experimental Clotiazepam The metabolism of Clotiazepam can be decreased when combined with Ziprasidone. Approved, Illicit Clotrimazole The metabolism of Ziprasidone can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine Clozapine may increase the QTc-prolonging activities of Ziprasidone. Approved Cobicistat The metabolism of Ziprasidone can be decreased when combined with Cobicistat. Approved Cobimetinib The serum concentration of Cobimetinib can be increased when it is combined with Ziprasidone. Approved, Investigational Cocaine The metabolism of Cocaine can be decreased when combined with Ziprasidone. Approved, Illicit Codeine The therapeutic efficacy of Codeine can be decreased when used in combination with Ziprasidone. Approved, Illicit Colchicine The serum concentration of Colchicine can be increased when it is combined with Ziprasidone. Approved Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Ziprasidone. Approved, Investigational Conjugated estrogens The metabolism of Conjugated estrogens can be decreased when combined with Ziprasidone. Approved Copanlisib The metabolism of Copanlisib can be decreased when combined with Ziprasidone. Approved, Investigational Cortisone acetate The metabolism of Cortisone acetate can be decreased when combined with Ziprasidone. Approved, Investigational Crizotinib Crizotinib may increase the QTc-prolonging activities of Ziprasidone. Approved Curcumin The metabolism of Ziprasidone can be decreased when combined with Curcumin. Approved, Investigational Cyclandelate The risk or severity of hypotension can be increased when Ziprasidone is combined with Cyclandelate. Approved Cyclizine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Cyclizine. Approved Cyclobenzaprine The metabolism of Cyclobenzaprine can be decreased when combined with Ziprasidone. Approved Cyclophosphamide The metabolism of Cyclophosphamide can be decreased when combined with Ziprasidone. Approved, Investigational Cyclopropane The risk or severity of adverse effects can be increased when Ziprasidone is combined with Cyclopropane. Experimental Cyclosporine The metabolism of Cyclosporine can be decreased when combined with Ziprasidone. Approved, Investigational, Vet Approved Cyproheptadine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Cyproheptadine. Approved Cyproterone acetate The serum concentration of Ziprasidone can be decreased when it is combined with Cyproterone acetate. Approved, Investigational Cytarabine The metabolism of Cytarabine can be decreased when combined with Ziprasidone. Approved, Investigational Dabrafenib The serum concentration of Ziprasidone can be decreased when it is combined with Dabrafenib. Approved, Investigational Daclatasvir The metabolism of Daclatasvir can be decreased when combined with Ziprasidone. Approved, Investigational Dantrolene The metabolism of Dantrolene can be decreased when combined with Ziprasidone. Approved, Investigational Dapagliflozin The metabolism of Dapagliflozin can be decreased when combined with Ziprasidone. Approved Dapiprazole Ziprasidone may increase the antihypertensive activities of Dapiprazole. Approved Dapoxetine The serum concentration of Dapoxetine can be increased when it is combined with Ziprasidone. Investigational Dapsone The metabolism of Dapsone can be decreased when combined with Ziprasidone. Approved, Investigational Darifenacin The metabolism of Darifenacin can be decreased when combined with Ziprasidone. Approved, Investigational Darodipine The risk or severity of hypotension can be increased when Ziprasidone is combined with Darodipine. Experimental Darunavir The metabolism of Ziprasidone can be decreased when combined with Darunavir. Approved Dasabuvir The metabolism of Dasabuvir can be decreased when combined with Ziprasidone. Approved Dasatinib The serum concentration of Ziprasidone can be increased when it is combined with Dasatinib. Approved, Investigational Daunorubicin The metabolism of Daunorubicin can be decreased when combined with Ziprasidone. Approved Debrisoquin The metabolism of Debrisoquin can be decreased when combined with Ziprasidone. Approved, Investigational Deferasirox The serum concentration of Ziprasidone can be decreased when it is combined with Deferasirox. Approved, Investigational Deflazacort The metabolism of Deflazacort can be decreased when combined with Ziprasidone. Approved, Investigational Degarelix Degarelix may increase the QTc-prolonging activities of Ziprasidone. Approved Delamanid The metabolism of Delamanid can be decreased when combined with Ziprasidone. Approved, Investigational Delavirdine The metabolism of Delavirdine can be decreased when combined with Ziprasidone. Approved Deoxyspergualin The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Ziprasidone. Investigational Deramciclane The risk or severity of adverse effects can be increased when Ziprasidone is combined with Deramciclane. Investigational Desflurane Desflurane may increase the QTc-prolonging activities of Ziprasidone. Approved Desipramine Desipramine may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Desloratadine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Desloratadine. Approved, Investigational Desvenlafaxine The metabolism of Desvenlafaxine can be decreased when combined with Ziprasidone. Approved, Investigational Detomidine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Detomidine. Vet Approved Deutetrabenazine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Deutetrabenazine. Approved, Investigational Dexamethasone The metabolism of Dexamethasone can be decreased when combined with Ziprasidone. Approved, Investigational, Vet Approved Dexbrompheniramine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dexbrompheniramine. Approved Dexchlorpheniramine maleate The metabolism of Dexchlorpheniramine maleate can be decreased when combined with Ziprasidone. Approved Dexfenfluramine The metabolism of Dexfenfluramine can be decreased when combined with Ziprasidone. Approved, Illicit, Investigational, Withdrawn Dexlansoprazole The metabolism of Dexlansoprazole can be decreased when combined with Ziprasidone. Approved, Investigational Dexmedetomidine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dexmedetomidine. Approved, Vet Approved Dexmethylphenidate The metabolism of Dexmethylphenidate can be decreased when combined with Ziprasidone. Approved, Investigational Dextroamphetamine Ziprasidone may increase the antihypertensive activities of Dextroamphetamine. Approved, Illicit Dextromethorphan The metabolism of Dextromethorphan can be decreased when combined with Ziprasidone. Approved Dextromoramide The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dextromoramide. Experimental, Illicit Dextropropoxyphene The metabolism of Dextropropoxyphene can be decreased when combined with Ziprasidone. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dezocine. Approved, Investigational Diazepam The metabolism of Diazepam can be decreased when combined with Ziprasidone. Approved, Illicit, Investigational, Vet Approved Diclofenac The metabolism of Diclofenac can be decreased when combined with Ziprasidone. Approved, Vet Approved Dienogest The metabolism of Dienogest can be decreased when combined with Ziprasidone. Approved Diethyl ether The risk or severity of adverse effects can be increased when Ziprasidone is combined with Diethyl ether. Experimental Diethylpropion Ziprasidone may decrease the stimulatory activities of Diethylpropion. Approved, Illicit Difenoxin The risk or severity of adverse effects can be increased when Ziprasidone is combined with Difenoxin. Approved, Illicit Digitoxin The metabolism of Digitoxin can be decreased when combined with Ziprasidone. Approved, Investigational Digoxin The metabolism of Digoxin can be decreased when combined with Ziprasidone. Approved Dihydro-alpha-ergocryptine The metabolism of Dihydro-alpha-ergocryptine can be decreased when combined with Ziprasidone. Approved Dihydrocodeine The metabolism of Dihydrocodeine can be decreased when combined with Ziprasidone. Approved, Illicit Dihydroergocornine The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ziprasidone. Approved Dihydroergocristine The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ziprasidone. Approved, Experimental Dihydroergocryptine The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Ziprasidone. Experimental Dihydroergotamine The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ziprasidone. Approved, Investigational Dihydroetorphine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dihydroetorphine. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dihydromorphine. Experimental, Illicit Diltiazem The metabolism of Diltiazem can be decreased when combined with Ziprasidone. Approved, Investigational Dimenhydrinate The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dimenhydrinate. Approved Diphenhydramine Diphenhydramine may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Ziprasidone is combined with Diphenoxylate. Approved, Illicit Dipivefrin Ziprasidone may decrease the vasoconstricting activities of Dipivefrin. Approved Dipyridamole Dipyridamole may increase the hypotensive activities of Ziprasidone. Approved Disopyramide The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Disopyramide. Approved Disulfiram The metabolism of Disulfiram can be decreased when combined with Ziprasidone. Approved Dixyrazine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dixyrazine. Experimental DL-Methylephedrine Ziprasidone may decrease the vasoconstricting activities of DL-Methylephedrine. Approved Dobutamine Ziprasidone may decrease the vasoconstricting activities of Dobutamine. Approved Docetaxel The metabolism of Docetaxel can be decreased when combined with Ziprasidone. Approved, Investigational Dofetilide The serum concentration of Dofetilide can be increased when it is combined with Ziprasidone. Approved, Investigational Dolasetron Dolasetron may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Domperidone The serum concentration of Domperidone can be increased when it is combined with Ziprasidone. Approved, Investigational, Vet Approved Donepezil The metabolism of Donepezil can be decreased when combined with Ziprasidone. Approved Dopamine The metabolism of Dopamine can be decreased when combined with Ziprasidone. Approved Dopexamine Ziprasidone may decrease the vasoconstricting activities of Dopexamine. Approved, Investigational Doramectin The risk or severity of adverse effects can be increased when Ziprasidone is combined with Doramectin. Vet Approved Dorzolamide The metabolism of Dorzolamide can be decreased when combined with Ziprasidone. Approved Dosulepin The metabolism of Ziprasidone can be decreased when combined with Dosulepin. Approved Dotarizine The risk or severity of hypotension can be increased when Ziprasidone is combined with Dotarizine. Investigational Doxazosin Doxazosin may increase the antihypertensive activities of Ziprasidone. Approved Doxepin Ziprasidone may increase the antihypertensive activities of Doxepin. Approved, Investigational Doxofylline Ziprasidone may decrease the vasoconstricting activities of Doxofylline. Approved, Investigational Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Ziprasidone. Approved, Investigational Doxorubicin The metabolism of Doxorubicin can be decreased when combined with Ziprasidone. Approved, Investigational Doxycycline The metabolism of Ziprasidone can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Ziprasidone is combined with DPDPE. Experimental Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone. Approved, Illicit Dronedarone The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Dronedarone. Approved Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone. Approved, Vet Approved Drotebanol The risk or severity of adverse effects can be increased when Ziprasidone is combined with Drotebanol. Experimental, Illicit Droxidopa Ziprasidone may increase the hypertensive activities of Droxidopa. Approved, Investigational Dulaglutide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Ziprasidone. Approved, Investigational Duloxetine The metabolism of Duloxetine can be decreased when combined with Ziprasidone. Approved Dutasteride The metabolism of Dutasteride can be decreased when combined with Ziprasidone. Approved, Investigational Dyclonine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dyclonine. Approved Ecgonine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Ecgonine. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Ziprasidone is combined with Ecopipam. Investigational Efavirenz The metabolism of Efavirenz can be decreased when combined with Ziprasidone. Approved, Investigational Efonidipine The risk or severity of hypotension can be increased when Ziprasidone is combined with Efonidipine. Approved, Investigational Elbasvir The metabolism of Elbasvir can be decreased when combined with Ziprasidone. Approved Eletriptan The serum concentration of Eletriptan can be increased when it is combined with Ziprasidone. Approved, Investigational Eliglustat The serum concentration of Eliglustat can be increased when it is combined with Ziprasidone. Approved Eltanolone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Eltanolone. Investigational Elvitegravir The metabolism of Elvitegravir can be decreased when combined with Ziprasidone. Approved Empagliflozin The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ziprasidone. Approved Enalapril The metabolism of Enalapril can be decreased when combined with Ziprasidone. Approved, Vet Approved Enasidenib The metabolism of Enasidenib can be decreased when combined with Ziprasidone. Approved, Investigational Encainide The metabolism of Encainide can be decreased when combined with Ziprasidone. Approved, Investigational, Withdrawn Enclomiphene The metabolism of Enclomiphene can be decreased when combined with Ziprasidone. Investigational Enflurane The risk or severity of adverse effects can be increased when Ziprasidone is combined with Enflurane. Approved, Investigational, Vet Approved Englitazone The therapeutic efficacy of Englitazone can be decreased when used in combination with Ziprasidone. Experimental Entacapone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Entacapone. Approved, Investigational Enzalutamide The serum concentration of Ziprasidone can be decreased when it is combined with Enzalutamide. Approved Epanolol Epanolol may increase the orthostatic hypotensive activities of Ziprasidone. Experimental Eperisone The risk or severity of hypotension can be increased when Ziprasidone is combined with Eperisone. Approved, Investigational Ephedra Ziprasidone may decrease the vasoconstricting activities of Ephedra. Approved, Nutraceutical, Withdrawn Ephedrine Ziprasidone may decrease the vasoconstricting activities of Ephedrine. Approved Epinastine The metabolism of Epinastine can be decreased when combined with Ziprasidone. Approved, Investigational Epinephrine Ziprasidone may increase the antihypertensive activities of Epinephrine. Approved, Vet Approved Eplerenone The serum concentration of Eplerenone can be increased when it is combined with Ziprasidone. Approved Ergocalciferol The metabolism of Ergocalciferol can be decreased when combined with Ziprasidone. Approved, Nutraceutical Ergoloid mesylate Ergoloid mesylate may increase the vasoconstricting activities of Ziprasidone. Approved Ergonovine The risk or severity of adverse effects can be increased when Ergonovine is combined with Ziprasidone. Approved Ergotamine The risk or severity of adverse effects can be increased when Ergotamine is combined with Ziprasidone. Approved Eribulin Eribulin may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Erlotinib The metabolism of Erlotinib can be decreased when combined with Ziprasidone. Approved, Investigational Erythromycin Erythromycin may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational, Vet Approved Esatenolol Esatenolol may increase the orthostatic hypotensive activities of Ziprasidone. Experimental Escitalopram The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Escitalopram. Approved, Investigational Esmirtazapine The metabolism of Esmirtazapine can be decreased when combined with Ziprasidone. Investigational Esmolol Esmolol may increase the orthostatic hypotensive activities of Ziprasidone. Approved Esomeprazole The metabolism of Esomeprazole can be decreased when combined with Ziprasidone. Approved, Investigational Estazolam The metabolism of Estazolam can be decreased when combined with Ziprasidone. Approved, Illicit Estradiol The metabolism of Estradiol can be decreased when combined with Ziprasidone. Approved, Investigational, Vet Approved Estradiol acetate The metabolism of Estradiol acetate can be decreased when combined with Ziprasidone. Approved, Investigational, Vet Approved Estradiol benzoate The metabolism of Estradiol benzoate can be decreased when combined with Ziprasidone. Approved, Investigational, Vet Approved Estradiol cypionate The metabolism of Estradiol cypionate can be decreased when combined with Ziprasidone. Approved, Investigational, Vet Approved Estradiol dienanthate The metabolism of Estradiol dienanthate can be decreased when combined with Ziprasidone. Approved, Investigational, Vet Approved Estradiol valerate The metabolism of Estradiol valerate can be decreased when combined with Ziprasidone. Approved, Investigational, Vet Approved Estramustine The metabolism of Estramustine can be decreased when combined with Ziprasidone. Approved, Investigational Estrogens, esterified The metabolism of Estrogens, esterified can be decreased when combined with Ziprasidone. Approved Estrone The metabolism of Estrone can be decreased when combined with Ziprasidone. Approved Estrone sulfate The metabolism of Estrone sulfate can be decreased when combined with Ziprasidone. Approved Eszopiclone The metabolism of Eszopiclone can be decreased when combined with Ziprasidone. Approved, Investigational Etafedrine Ziprasidone may decrease the vasoconstricting activities of Etafedrine. Approved Ethanol Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Ziprasidone is combined with Ethchlorvynol. Approved, Illicit, Withdrawn Ethinyl Estradiol The metabolism of Ethinyl Estradiol can be decreased when combined with Ziprasidone. Approved Ethosuximide The metabolism of Ethosuximide can be decreased when combined with Ziprasidone. Approved Ethotoin The risk or severity of adverse effects can be increased when Ziprasidone is combined with Ethotoin. Approved Ethyl carbamate The risk or severity of adverse effects can be increased when Ziprasidone is combined with Ethyl carbamate. Withdrawn Ethyl chloride The risk or severity of adverse effects can be increased when Ziprasidone is combined with Ethyl chloride. Approved, Experimental, Investigational Ethyl loflazepate The risk or severity of adverse effects can be increased when Ziprasidone is combined with Ethyl loflazepate. Approved, Illicit Ethylmorphine The metabolism of Ethylmorphine can be decreased when combined with Ziprasidone. Approved, Illicit Etidocaine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Etidocaine. Approved Etifoxine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Etifoxine. Investigational, Withdrawn Etilefrine Ziprasidone may decrease the vasoconstricting activities of Etilefrine. Withdrawn Etizolam The risk or severity of adverse effects can be increased when Ziprasidone is combined with Etizolam. Approved Etomidate The risk or severity of adverse effects can be increased when Ziprasidone is combined with Etomidate. Approved Etonogestrel The metabolism of Etonogestrel can be decreased when combined with Ziprasidone. Approved, Investigational Etoperidone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Etoperidone. Withdrawn Etoposide The metabolism of Etoposide can be decreased when combined with Ziprasidone. Approved Etoricoxib The metabolism of Etoricoxib can be decreased when combined with Ziprasidone. Approved, Investigational Etorphine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Etorphine. Illicit, Vet Approved Etravirine The metabolism of Etravirine can be decreased when combined with Ziprasidone. Approved Everolimus The serum concentration of Everolimus can be increased when it is combined with Ziprasidone. Approved Exemestane The metabolism of Exemestane can be decreased when combined with Ziprasidone. Approved, Investigational Exenatide The therapeutic efficacy of Exenatide can be decreased when used in combination with Ziprasidone. Approved, Investigational Ezogabine Ezogabine may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Famciclovir The metabolism of Famciclovir can be decreased when combined with Ziprasidone. Approved, Investigational Famotidine Famotidine may increase the QTc-prolonging activities of Ziprasidone. Approved Felbamate Felbamate may increase the QTc-prolonging activities of Ziprasidone. Approved Felodipine The metabolism of Felodipine can be decreased when combined with Ziprasidone. Approved, Investigational Fencamfamine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Fencamfamine. Approved, Illicit, Withdrawn Fendiline The risk or severity of hypotension can be increased when Ziprasidone is combined with Fendiline. Withdrawn Fenofibrate The metabolism of Fenofibrate can be decreased when combined with Ziprasidone. Approved Fenoterol Ziprasidone may decrease the vasoconstricting activities of Fenoterol. Approved, Investigational Fentanyl The serum concentration of Fentanyl can be increased when it is combined with Ziprasidone. Approved, Illicit, Investigational, Vet Approved Fesoterodine The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ziprasidone. Approved Fexofenadine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Fexofenadine. Approved, Investigational Finasteride The metabolism of Finasteride can be decreased when combined with Ziprasidone. Approved Fingolimod Fingolimod may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Fish oil The risk or severity of hypotension can be increased when Ziprasidone is combined with Fish oil. Approved, Nutraceutical Flecainide Flecainide may increase the QTc-prolonging activities of Ziprasidone. Approved, Withdrawn Flibanserin The risk or severity of adverse effects can be increased when Ziprasidone is combined with Flibanserin. Approved, Investigational Fluanisone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Fluanisone. Experimental Fluconazole Fluconazole may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Fludiazepam The risk or severity of adverse effects can be increased when Ziprasidone is combined with Fludiazepam. Approved, Illicit Flunarizine The metabolism of Flunarizine can be decreased when combined with Ziprasidone. Approved Flunisolide The metabolism of Flunisolide can be decreased when combined with Ziprasidone. Approved, Investigational Flunitrazepam The metabolism of Flunitrazepam can be decreased when combined with Ziprasidone. Approved, Illicit Fluorometholone The metabolism of Fluorometholone can be decreased when combined with Ziprasidone. Approved, Investigational Fluoxetine Fluoxetine may increase the QTc-prolonging activities of Ziprasidone. Approved, Vet Approved Flupentixol The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Flupentixol. Approved, Investigational, Withdrawn Fluphenazine The metabolism of Fluphenazine can be decreased when combined with Ziprasidone. Approved Flurazepam The metabolism of Flurazepam can be decreased when combined with Ziprasidone. Approved, Illicit, Investigational Fluspirilene The risk or severity of adverse effects can be increased when Ziprasidone is combined with Fluspirilene. Approved, Investigational Flutamide The metabolism of Flutamide can be decreased when combined with Ziprasidone. Approved, Investigational Fluticasone furoate The metabolism of Fluticasone furoate can be decreased when combined with Ziprasidone. Approved Fluticasone propionate The metabolism of Fluticasone propionate can be decreased when combined with Ziprasidone. Approved Fluvastatin The serum concentration of Fluvastatin can be increased when it is combined with Ziprasidone. Approved Fluvoxamine The metabolism of Ziprasidone can be decreased when combined with Fluvoxamine. Approved, Investigational Formoterol Formoterol may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Fosamprenavir The metabolism of Fosamprenavir can be decreased when combined with Ziprasidone. Approved Fosaprepitant The serum concentration of Ziprasidone can be increased when it is combined with Fosaprepitant. Approved Foscarnet Foscarnet may increase the QTc-prolonging activities of Ziprasidone. Approved Fosnetupitant The metabolism of Fosnetupitant can be decreased when combined with Ziprasidone. Approved Fosphenytoin The metabolism of Ziprasidone can be increased when combined with Fosphenytoin. Approved, Investigational Fospropofol The risk or severity of adverse effects can be increased when Ziprasidone is combined with Fospropofol. Approved, Illicit, Investigational Fostamatinib Fostamatinib may increase the hypotensive activities of Ziprasidone. Approved, Investigational Frovatriptan The risk or severity of adverse effects can be increased when Frovatriptan is combined with Ziprasidone. Approved, Investigational Fulvestrant The metabolism of Fulvestrant can be decreased when combined with Ziprasidone. Approved, Investigational Furazolidone The metabolism of Ziprasidone can be decreased when combined with Furazolidone. Approved, Investigational, Vet Approved Fusidic Acid The serum concentration of Ziprasidone can be increased when it is combined with Fusidic Acid. Approved, Investigational Gabapentin The risk or severity of adverse effects can be increased when Ziprasidone is combined with Gabapentin. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Ziprasidone is combined with Gabapentin Enacarbil. Approved, Investigational Gadobenic acid Gadobenic acid may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Galantamine Galantamine may increase the QTc-prolonging activities of Ziprasidone. Approved Gallopamil The risk or severity of hypotension can be increased when Ziprasidone is combined with Gallopamil. Investigational Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Ziprasidone is combined with Gamma Hydroxybutyric Acid. Approved, Illicit, Investigational Gefitinib The metabolism of Gefitinib can be decreased when combined with Ziprasidone. Approved, Investigational Gemfibrozil The metabolism of Gemfibrozil can be decreased when combined with Ziprasidone. Approved Gemifloxacin Gemifloxacin may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Gepefrine Ziprasidone may decrease the stimulatory activities of Gepefrine. Experimental Gepirone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Gepirone. Investigational Glibornuride The therapeutic efficacy of Glibornuride can be decreased when used in combination with Ziprasidone. Investigational, Withdrawn Gliclazide The therapeutic efficacy of Gliclazide can be decreased when used in combination with Ziprasidone. Approved Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Ziprasidone. Approved Glipizide The metabolism of Glipizide can be decreased when combined with Ziprasidone. Approved, Investigational Gliquidone The therapeutic efficacy of Gliquidone can be decreased when used in combination with Ziprasidone. Approved, Investigational Glutethimide The risk or severity of adverse effects can be increased when Ziprasidone is combined with Glutethimide. Approved, Illicit Glyburide The metabolism of Glyburide can be decreased when combined with Ziprasidone. Approved Goserelin Goserelin may increase the QTc-prolonging activities of Ziprasidone. Approved Granisetron Granisetron may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Grazoprevir The metabolism of Grazoprevir can be decreased when combined with Ziprasidone. Approved Grepafloxacin The metabolism of Grepafloxacin can be decreased when combined with Ziprasidone. Approved, Investigational, Withdrawn Guanabenz Ziprasidone may decrease the vasoconstricting activities of Guanabenz. Approved, Investigational Guanfacine The metabolism of Guanfacine can be decreased when combined with Ziprasidone. Approved, Investigational Gusperimus The therapeutic efficacy of Gusperimus can be decreased when used in combination with Ziprasidone. Investigational Halazepam The risk or severity of adverse effects can be increased when Ziprasidone is combined with Halazepam. Approved, Illicit, Withdrawn Halofantrine The serum concentration of Halofantrine can be increased when it is combined with Ziprasidone. Approved Haloperidol Haloperidol may increase the QTc-prolonging activities of Ziprasidone. Approved Halothane The metabolism of Halothane can be decreased when combined with Ziprasidone. Approved, Vet Approved Harmaline The metabolism of Ziprasidone can be decreased when combined with Harmaline. Experimental Heroin The risk or severity of adverse effects can be increased when Ziprasidone is combined with Heroin. Approved, Illicit, Investigational Hexobarbital The metabolism of Hexobarbital can be decreased when combined with Ziprasidone. Approved Hexoprenaline Ziprasidone may decrease the vasoconstricting activities of Hexoprenaline. Approved, Withdrawn Higenamine Ziprasidone may decrease the vasoconstricting activities of Higenamine. Investigational Histamine The metabolism of Histamine can be decreased when combined with Ziprasidone. Approved, Investigational Histrelin Histrelin may increase the QTc-prolonging activities of Ziprasidone. Approved Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ziprasidone. Approved, Investigational Hydracarbazine The metabolism of Ziprasidone can be decreased when combined with Hydracarbazine. Experimental Hydrocodone Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydrocortisone The metabolism of Hydrocortisone can be decreased when combined with Ziprasidone. Approved, Vet Approved Hydromorphone The metabolism of Hydromorphone can be decreased when combined with Ziprasidone. Approved, Illicit Hydroxyamphetamine Ziprasidone may decrease the stimulatory activities of Hydroxyamphetamine. Approved Hydroxyprogesterone caproate The metabolism of Hydroxyprogesterone caproate can be decreased when combined with Ziprasidone. Approved, Investigational Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone. Approved Ibandronate Ibandronate may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Ibrutinib The serum concentration of Ibrutinib can be increased when it is combined with Ziprasidone. Approved Ibutilide The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Ibutilide. Approved Icotinib The metabolism of Icotinib can be decreased when combined with Ziprasidone. Approved, Investigational Idarubicin The metabolism of Idarubicin can be decreased when combined with Ziprasidone. Approved Idelalisib The metabolism of Ziprasidone can be decreased when combined with Idelalisib. Approved Ifosfamide The serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Ziprasidone resulting in a loss in efficacy. Approved Iloperidone The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Iloperidone. Approved Imatinib The serum concentration of Imatinib can be increased when it is combined with Ziprasidone. Approved Imidafenacin The metabolism of Imidafenacin can be decreased when combined with Ziprasidone. Approved, Investigational Imipramine Ziprasidone may increase the antihypertensive activities of Imipramine. Approved Imiquimod The metabolism of Imiquimod can be decreased when combined with Ziprasidone. Approved, Investigational Indacaterol Indacaterol may increase the QTc-prolonging activities of Ziprasidone. Approved Indalpine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Indalpine. Investigational, Withdrawn Indapamide Indapamide may increase the QTc-prolonging activities of Ziprasidone. Approved Indenolol Indenolol may increase the orthostatic hypotensive activities of Ziprasidone. Withdrawn Indinavir The metabolism of Ziprasidone can be decreased when combined with Indinavir. Approved Indiplon The risk or severity of adverse effects can be increased when Ziprasidone is combined with Indiplon. Investigational Indoramin Indoramin may increase the antihypertensive activities of Ziprasidone. Withdrawn Insulin Aspart The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Ziprasidone. Approved Insulin Detemir The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Ziprasidone. Approved Insulin Glargine The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Ziprasidone. Approved Insulin Glulisine The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Ziprasidone. Approved Insulin Human The therapeutic efficacy of Insulin Human can be decreased when used in combination with Ziprasidone. Approved, Investigational Insulin Lispro The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ziprasidone. Approved Insulin Pork The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Ziprasidone. Approved Iofetamine I-123 Ziprasidone may decrease the stimulatory activities of Iofetamine I-123. Approved Ipecac The metabolism of Ipecac can be decreased when combined with Ziprasidone. Approved, Withdrawn Ipratropium The metabolism of Ipratropium bromide can be decreased when combined with Ziprasidone. Approved Iproclozide The metabolism of Ziprasidone can be decreased when combined with Iproclozide. Withdrawn Iproniazid The metabolism of Ziprasidone can be decreased when combined with Iproniazid. Withdrawn Irinotecan The metabolism of Irinotecan can be decreased when combined with Ziprasidone. Approved, Investigational Isavuconazole The serum concentration of Ziprasidone can be increased when it is combined with Isavuconazole. Approved, Investigational Isavuconazonium The metabolism of Isavuconazonium can be decreased when combined with Ziprasidone. Approved, Investigational Isocarboxazid The therapeutic efficacy of Ziprasidone can be increased when used in combination with Isocarboxazid. Approved Isoetarine Ziprasidone may decrease the vasoconstricting activities of Isoetarine. Approved Isoflurane Isoflurane may increase the QTc-prolonging activities of Ziprasidone. Approved, Vet Approved Isometheptene Ziprasidone may decrease the vasoconstricting activities of Isometheptene. Approved Isoprenaline Ziprasidone may decrease the vasoconstricting activities of Isoprenaline. Approved, Investigational Isosorbide Dinitrate The metabolism of Isosorbide Dinitrate can be decreased when combined with Ziprasidone. Approved, Investigational Isosorbide Mononitrate The metabolism of Isosorbide Mononitrate can be decreased when combined with Ziprasidone. Approved Isoxsuprine Ziprasidone may decrease the vasoconstricting activities of Isoxsuprine. Approved, Withdrawn Isradipine Isradipine may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Itraconazole The metabolism of Ziprasidone can be decreased when combined with Itraconazole. Approved, Investigational Ivabradine The serum concentration of Ivabradine can be increased when it is combined with Ziprasidone. Approved Ivacaftor The serum concentration of Ivacaftor can be increased when it is combined with Ziprasidone. Approved Ivermectin The metabolism of Ivermectin can be decreased when combined with Ziprasidone. Approved, Investigational, Vet Approved Ixabepilone The metabolism of Ixabepilone can be decreased when combined with Ziprasidone. Approved, Investigational Ixazomib The metabolism of Ixazomib can be decreased when combined with Ziprasidone. Approved, Investigational Ketamine The metabolism of Ketamine can be decreased when combined with Ziprasidone. Approved, Vet Approved Ketazolam The metabolism of Ketazolam can be decreased when combined with Ziprasidone. Approved Ketobemidone The metabolism of Ketobemidone can be decreased when combined with Ziprasidone. Approved, Investigational Ketoconazole The metabolism of Ziprasidone can be decreased when combined with Ketoconazole. Approved, Investigational Labetalol Labetalol may increase the antihypertensive activities of Ziprasidone. Approved Lacidipine The metabolism of Lacidipine can be decreased when combined with Ziprasidone. Approved, Investigational Lamotrigine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Lamotrigine. Approved, Investigational Landiolol Landiolol may increase the orthostatic hypotensive activities of Ziprasidone. Investigational Lansoprazole The metabolism of Lansoprazole can be decreased when combined with Ziprasidone. Approved, Investigational Lapatinib Lapatinib may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Laquinimod The metabolism of Laquinimod can be decreased when combined with Ziprasidone. Investigational Lenvatinib Lenvatinib may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Lercanidipine The metabolism of Lercanidipine can be decreased when combined with Ziprasidone. Approved, Investigational Letermovir The metabolism of Letermovir can be decreased when combined with Ziprasidone. Approved, Investigational Letrozole The metabolism of Letrozole can be decreased when combined with Ziprasidone. Approved, Investigational Leuprolide Leuprolide may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Levetiracetam The risk or severity of adverse effects can be increased when Ziprasidone is combined with Levetiracetam. Approved, Investigational Levobetaxolol Levobetaxolol may increase the orthostatic hypotensive activities of Ziprasidone. Approved, Investigational Levobupivacaine The metabolism of Levobupivacaine can be decreased when combined with Ziprasidone. Approved, Investigational Levocabastine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Levocabastine. Approved, Investigational Levocetirizine The metabolism of Levocetirizine can be decreased when combined with Ziprasidone. Approved Levodopa The therapeutic efficacy of Levodopa can be decreased when used in combination with Ziprasidone. Approved Levofloxacin Levofloxacin may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Levomethadyl Acetate The metabolism of Levomethadyl Acetate can be decreased when combined with Ziprasidone. Approved, Investigational Levomilnacipran The metabolism of Levomilnacipran can be decreased when combined with Ziprasidone. Approved, Investigational Levonorgestrel The metabolism of Levonorgestrel can be decreased when combined with Ziprasidone. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Ziprasidone is combined with Levorphanol. Approved Levosalbutamol Ziprasidone may decrease the vasoconstricting activities of Levosalbutamol. Approved, Investigational Levothyroxine The metabolism of Levothyroxine can be decreased when combined with Ziprasidone. Approved Lidocaine The metabolism of Lidocaine can be decreased when combined with Ziprasidone. Approved, Vet Approved Lidoflazine The risk or severity of hypotension can be increased when Ziprasidone is combined with Lidoflazine. Experimental Linagliptin The therapeutic efficacy of Linagliptin can be decreased when used in combination with Ziprasidone. Approved Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Ziprasidone. Approved, Investigational Liraglutide The therapeutic efficacy of Liraglutide can be decreased when used in combination with Ziprasidone. Approved Lisdexamfetamine Ziprasidone may increase the antihypertensive activities of Lisdexamfetamine. Approved, Investigational Lisuride The risk or severity of adverse effects can be increased when Lisuride is combined with Ziprasidone. Approved, Investigational Lithium cation Lithium may increase the neurotoxic activities of Ziprasidone. Experimental Lobeglitazone The metabolism of Ziprasidone can be decreased when combined with Lobeglitazone. Approved, Investigational Lofentanil The risk or severity of adverse effects can be increased when Ziprasidone is combined with Lofentanil. Illicit Lofexidine The therapeutic efficacy of Ziprasidone can be increased when used in combination with Lofexidine. Approved, Investigational Lomitapide The serum concentration of Lomitapide can be increased when it is combined with Ziprasidone. Approved, Investigational Lomustine The metabolism of Lomustine can be decreased when combined with Ziprasidone. Approved, Investigational Loperamide The metabolism of Loperamide can be decreased when combined with Ziprasidone. Approved Lopinavir The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Lopinavir. Approved Loprazolam The risk or severity of adverse effects can be increased when Ziprasidone is combined with Loprazolam. Experimental Loratadine The metabolism of Loratadine can be decreased when combined with Ziprasidone. Approved, Investigational Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Ziprasidone. Approved Lorcaserin The metabolism of Lorcaserin can be decreased when combined with Ziprasidone. Approved Lormetazepam The risk or severity of adverse effects can be increased when Ziprasidone is combined with Lormetazepam. Approved Lorpiprazole The serum concentration of Ziprasidone can be increased when it is combined with Lorpiprazole. Approved Losartan The metabolism of Losartan can be decreased when combined with Ziprasidone. Approved Lovastatin The serum concentration of Lovastatin can be increased when it is combined with Ziprasidone. Approved, Investigational Loxapine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Loxapine. Approved Luliconazole The serum concentration of Ziprasidone can be increased when it is combined with Luliconazole. Approved Lumacaftor The metabolism of Ziprasidone can be increased when combined with Lumacaftor. Approved Lumefantrine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Lumefantrine. Approved Lurasidone The serum concentration of Lurasidone can be increased when it is combined with Ziprasidone. Approved, Investigational Lysergic Acid Diethylamide The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Ziprasidone. Illicit, Investigational, Withdrawn Macimorelin The metabolism of Macimorelin can be decreased when combined with Ziprasidone. Approved, Investigational Macitentan The metabolism of Macitentan can be decreased when combined with Ziprasidone. Approved Magnesium sulfate The therapeutic efficacy of Ziprasidone can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Manidipine The risk or severity of hypotension can be increased when Ziprasidone is combined with Manidipine. Approved, Investigational Maprotiline Maprotiline may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Maraviroc The metabolism of Maraviroc can be decreased when combined with Ziprasidone. Approved, Investigational Mebanazine The metabolism of Ziprasidone can be decreased when combined with Mebanazine. Withdrawn Mebendazole The metabolism of Mebendazole can be decreased when combined with Ziprasidone. Approved, Vet Approved Mebicar The risk or severity of adverse effects can be increased when Ziprasidone is combined with Mebicar. Experimental Meclizine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Meclizine. Approved Medazepam The risk or severity of adverse effects can be increased when Ziprasidone is combined with Medazepam. Experimental Medetomidine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Medetomidine. Vet Approved Medical Cannabis The metabolism of Medical Cannabis can be decreased when combined with Ziprasidone. Experimental, Investigational Medroxyprogesterone acetate The metabolism of Medroxyprogesterone acetate can be decreased when combined with Ziprasidone. Approved, Investigational Mefloquine Mefloquine may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Melatonin The risk or severity of adverse effects can be increased when Ziprasidone is combined with Melatonin. Approved, Nutraceutical, Vet Approved Meloxicam The metabolism of Meloxicam can be decreased when combined with Ziprasidone. Approved, Vet Approved Melperone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Melperone. Approved, Investigational Menthol The risk or severity of hypotension can be increased when Ziprasidone is combined with Menthol. Approved Mephedrone Ziprasidone may decrease the stimulatory activities of Mephedrone. Investigational Mephentermine Ziprasidone may decrease the stimulatory activities of Mephentermine. Approved Mephenytoin The metabolism of Mephenytoin can be decreased when combined with Ziprasidone. Investigational, Withdrawn Mepindolol Mepindolol may increase the orthostatic hypotensive activities of Ziprasidone. Experimental Mepivacaine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Mepivacaine. Approved, Vet Approved Meprobamate The risk or severity of adverse effects can be increased when Ziprasidone is combined with Meprobamate. Approved, Illicit Meptazinol The risk or severity of adverse effects can be increased when Ziprasidone is combined with Meptazinol. Experimental Mequitazine Ziprasidone may increase the arrhythmogenic activities of Mequitazine. Approved Mesoridazine The metabolism of Mesoridazine can be decreased when combined with Ziprasidone. Approved, Investigational Metaraminol Ziprasidone may decrease the vasoconstricting activities of Metaraminol. Approved, Investigational Metaxalone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Metaxalone. Approved Metergoline The risk or severity of adverse effects can be increased when Metergoline is combined with Ziprasidone. Experimental Metformin The therapeutic efficacy of Metformin can be decreased when used in combination with Ziprasidone. Approved Methadone Methadone may increase the QTc-prolonging activities of Ziprasidone. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Ziprasidone is combined with Methadyl Acetate. Approved, Illicit Methamphetamine The metabolism of Methamphetamine can be decreased when combined with Ziprasidone. Approved, Illicit Methapyrilene The risk or severity of adverse effects can be increased when Ziprasidone is combined with Methapyrilene. Withdrawn Methaqualone The metabolism of Methaqualone can be decreased when combined with Ziprasidone. Illicit, Withdrawn Methocarbamol The risk or severity of adverse effects can be increased when Ziprasidone is combined with Methocarbamol. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Ziprasidone is combined with Methohexital. Approved Methotrimeprazine Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved, Investigational Methoxamine Ziprasidone may decrease the vasoconstricting activities of Methoxamine. Approved, Investigational Methoxsalen The metabolism of Methoxsalen can be decreased when combined with Ziprasidone. Approved Methoxyflurane The metabolism of Methoxyflurane can be decreased when combined with Ziprasidone. Approved, Investigational, Vet Approved Methoxyphenamine Ziprasidone may decrease the stimulatory activities of Methoxyphenamine. Experimental Methsuximide The risk or severity of adverse effects can be increased when Ziprasidone is combined with Methsuximide. Approved Methyldopa Ziprasidone may decrease the vasoconstricting activities of Methyldopa. Approved Methylecgonine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Methylecgonine. Experimental Methylene blue The metabolism of Ziprasidone can be decreased when combined with Methylene blue. Approved, Investigational Methylergometrine The risk or severity of adverse effects can be increased when Methylergometrine is combined with Ziprasidone. Approved Methylphenidate The risk or severity of adverse effects can be increased when Ziprasidone is combined with Methylphenidate. Approved, Investigational Methylphenobarbital The risk or severity of adverse effects can be increased when Ziprasidone is combined with Methylphenobarbital. Approved Methylprednisolone The metabolism of Methylprednisolone can be decreased when combined with Ziprasidone. Approved, Vet Approved Methyltestosterone The metabolism of Methyltestosterone can be decreased when combined with Ziprasidone. Approved Methyprylon The metabolism of Methyprylon can be decreased when combined with Ziprasidone. Approved, Illicit, Withdrawn Methysergide The risk or severity of adverse effects can be increased when Methysergide is combined with Ziprasidone. Approved Metoclopramide The risk or severity of adverse effects can be increased when Metoclopramide is combined with Ziprasidone. Approved, Investigational Metoclopramide Metoclopramide may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Metoprolol The serum concentration of Metoprolol can be increased when it is combined with Ziprasidone. Approved, Investigational Metronidazole Metronidazole may increase the QTc-prolonging activities of Ziprasidone. Approved Metyrosine Ziprasidone may increase the sedative activities of Metyrosine. Approved Mevastatin The serum concentration of Mevastatin can be increased when it is combined with Ziprasidone. Experimental Mexiletine The metabolism of Ziprasidone can be decreased when combined with Mexiletine. Approved, Investigational Mianserin The metabolism of Mianserin can be decreased when combined with Ziprasidone. Approved, Investigational Mibefradil The metabolism of Mibefradil can be decreased when combined with Ziprasidone. Investigational, Withdrawn Miconazole The metabolism of Miconazole can be decreased when combined with Ziprasidone. Approved, Investigational, Vet Approved Midazolam The metabolism of Midazolam can be decreased when combined with Ziprasidone. Approved, Illicit Midecamycin The metabolism of Midecamycin can be decreased when combined with Ziprasidone. Approved Midodrine Ziprasidone may decrease the vasoconstricting activities of Midodrine. Approved Midomafetamine Ziprasidone may decrease the stimulatory activities of Midomafetamine. Experimental, Illicit, Investigational Midostaurin The metabolism of Ziprasidone can be decreased when combined with Midostaurin. Approved, Investigational Mifepristone Ziprasidone may increase the QTc-prolonging activities of Mifepristone. Approved, Investigational Miglitol The therapeutic efficacy of Miglitol can be decreased when used in combination with Ziprasidone. Approved Miglustat The therapeutic efficacy of Miglustat can be decreased when used in combination with Ziprasidone. Approved Milnacipran The risk or severity of adverse effects can be increased when Ziprasidone is combined with Milnacipran. Approved, Investigational Minaprine The metabolism of Ziprasidone can be decreased when combined with Minaprine. Approved Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone. Approved, Investigational Mirabegron Mirabegron may increase the QTc-prolonging activities of Ziprasidone. Approved Mirodenafil Mirodenafil may increase the hypotensive activities of Ziprasidone. Investigational Mirtazapine Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved Mitiglinide The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Ziprasidone. Approved, Investigational Mitotane The serum concentration of Ziprasidone can be decreased when it is combined with Mitotane. Approved MMDA Ziprasidone may decrease the stimulatory activities of MMDA. Experimental, Illicit Moclobemide The metabolism of Ziprasidone can be decreased when combined with Moclobemide. Approved, Investigational Modafinil The metabolism of Modafinil can be decreased when combined with Ziprasidone. Approved, Investigational Moexipril Moexipril may increase the QTc-prolonging activities of Ziprasidone. Approved Molindone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Molindone. Approved Montelukast The metabolism of Montelukast can be decreased when combined with Ziprasidone. Approved Morphine The metabolism of Morphine can be decreased when combined with Ziprasidone. Approved, Investigational Moxifloxacin Moxifloxacin may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Moxonidine Ziprasidone may decrease the vasoconstricting activities of Moxonidine. Approved, Investigational Mycophenolate mofetil The metabolism of Mycophenolate mofetil can be decreased when combined with Ziprasidone. Approved, Investigational Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone. Approved, Investigational Nabiximols The metabolism of Nabiximols can be decreased when combined with Ziprasidone. Approved, Investigational Nadolol Nadolol may increase the orthostatic hypotensive activities of Ziprasidone. Approved Naftopidil The risk or severity of hypotension can be increased when Ziprasidone is combined with Naftopidil. Investigational Nalbuphine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Nalbuphine. Approved Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Ziprasidone. Approved Naloxone The metabolism of Naloxone can be decreased when combined with Ziprasidone. Approved, Vet Approved Naphazoline Ziprasidone may decrease the vasoconstricting activities of Naphazoline. Approved Naratriptan The risk or severity of adverse effects can be increased when Naratriptan is combined with Ziprasidone. Approved, Investigational Nateglinide The metabolism of Nateglinide can be decreased when combined with Ziprasidone. Approved, Investigational Nebivolol The serum concentration of Nebivolol can be increased when it is combined with Ziprasidone. Approved, Investigational Nefazodone Ziprasidone may increase the antihypertensive activities of Nefazodone. Approved, Withdrawn Nelfinavir The metabolism of Ziprasidone can be decreased when combined with Nelfinavir. Approved Neratinib The metabolism of Neratinib can be decreased when combined with Ziprasidone. Approved, Investigational Netupitant The serum concentration of Ziprasidone can be increased when it is combined with Netupitant. Approved, Investigational Nevirapine The metabolism of Ziprasidone can be increased when combined with Nevirapine. Approved Nialamide The metabolism of Ziprasidone can be decreased when combined with Nialamide. Withdrawn Nicardipine Ziprasidone may increase the antihypertensive activities of Nicardipine. Approved, Investigational Nicergoline The risk or severity of adverse effects can be increased when Nicergoline is combined with Ziprasidone. Approved, Investigational Nicotine The metabolism of Nicotine can be decreased when combined with Ziprasidone. Approved Nifedipine The metabolism of Nifedipine can be decreased when combined with Ziprasidone. Approved Niguldipine Ziprasidone may increase the antihypertensive activities of Niguldipine. Experimental Nilotinib The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Nilotinib. Approved, Investigational Niludipine The risk or severity of hypotension can be increased when Ziprasidone is combined with Niludipine. Experimental Nilvadipine The metabolism of Nilvadipine can be decreased when combined with Ziprasidone. Approved, Investigational Nimesulide The risk or severity of hypotension can be increased when Ziprasidone is combined with Nimesulide. Approved, Investigational, Withdrawn Nimodipine The serum concentration of Nimodipine can be increased when it is combined with Ziprasidone. Approved, Investigational Nisoldipine The metabolism of Nisoldipine can be decreased when combined with Ziprasidone. Approved Nitrazepam The metabolism of Nitrazepam can be decreased when combined with Ziprasidone. Approved Nitrendipine The metabolism of Nitrendipine can be decreased when combined with Ziprasidone. Approved, Investigational Nitrofural The metabolism of Nitrofural can be decreased when combined with Ziprasidone. Approved, Investigational, Vet Approved Nitrous oxide The risk or severity of adverse effects can be increased when Ziprasidone is combined with Nitrous oxide. Approved, Vet Approved Nordazepam The risk or severity of adverse effects can be increased when Ziprasidone is combined with Nordazepam. Approved Norepinephrine Ziprasidone may decrease the vasoconstricting activities of Norepinephrine. Approved Norethisterone The metabolism of Norethisterone can be decreased when combined with Ziprasidone. Approved Norfenefrine Ziprasidone may decrease the vasoconstricting activities of Norfenefrine. Experimental Norfloxacin Norfloxacin may increase the QTc-prolonging activities of Ziprasidone. Approved Norflurane The risk or severity of adverse effects can be increased when Ziprasidone is combined with Norflurane. Approved, Investigational Norgestrel The metabolism of Norgestrel can be decreased when combined with Ziprasidone. Approved Normethadone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Normethadone. Approved, Illicit Nortriptyline Ziprasidone may increase the antihypertensive activities of Nortriptyline. Approved Nylidrin Ziprasidone may decrease the vasoconstricting activities of Nylidrin. Approved Octamoxin The metabolism of Ziprasidone can be decreased when combined with Octamoxin. Withdrawn Octopamine Ziprasidone may decrease the vasoconstricting activities of Octopamine. Experimental Octreotide Octreotide may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Odanacatib The metabolism of Odanacatib can be decreased when combined with Ziprasidone. Investigational Ofloxacin Ofloxacin may increase the QTc-prolonging activities of Ziprasidone. Approved Olanzapine Ziprasidone may increase the antihypertensive activities of Olanzapine. Approved, Investigational Olaparib The serum concentration of Olaparib can be increased when it is combined with Ziprasidone. Approved Olodaterol Olodaterol may increase the QTc-prolonging activities of Ziprasidone. Approved Olopatadine The metabolism of Olopatadine can be decreased when combined with Ziprasidone. Approved Omeprazole The metabolism of Omeprazole can be decreased when combined with Ziprasidone. Approved, Investigational, Vet Approved Ondansetron Ondansetron may increase the QTc-prolonging activities of Ziprasidone. Approved Opium The risk or severity of adverse effects can be increased when Ziprasidone is combined with Opium. Approved, Illicit Orciprenaline Ziprasidone may decrease the vasoconstricting activities of Orciprenaline. Approved Orphenadrine Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Osanetant The risk or severity of adverse effects can be increased when Ziprasidone is combined with Osanetant. Investigational Osimertinib The serum concentration of Ziprasidone can be increased when it is combined with Osimertinib. Approved Ospemifene The metabolism of Ospemifene can be decreased when combined with Ziprasidone. Approved, Investigational Otilonium The risk or severity of hypotension can be increased when Ziprasidone is combined with Otilonium. Experimental, Investigational Oxazepam The metabolism of Oxazepam can be decreased when combined with Ziprasidone. Approved Oxprenolol Oxprenolol may increase the orthostatic hypotensive activities of Ziprasidone. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Oxybuprocaine. Approved, Investigational Oxybutynin The metabolism of Oxybutynin can be decreased when combined with Ziprasidone. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Oxycodone. Approved, Illicit, Investigational Oxyfedrine Ziprasidone may decrease the vasoconstricting activities of Oxyfedrine. Experimental Oxymetazoline Ziprasidone may decrease the vasoconstricting activities of Oxymetazoline. Approved, Investigational Oxymorphone The metabolism of Oxymorphone can be decreased when combined with Ziprasidone. Approved, Investigational, Vet Approved Oxytocin Oxytocin may increase the QTc-prolonging activities of Ziprasidone. Approved, Vet Approved Paclitaxel The metabolism of Paclitaxel can be decreased when combined with Ziprasidone. Approved, Vet Approved Palbociclib The serum concentration of Ziprasidone can be increased when it is combined with Palbociclib. Approved, Investigational Paliperidone The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Paliperidone. Approved Palonosetron The metabolism of Palonosetron can be decreased when combined with Ziprasidone. Approved, Investigational Panobinostat Panobinostat may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Pantoprazole The metabolism of Pantoprazole can be decreased when combined with Ziprasidone. Approved Paraldehyde Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved, Investigational Paramethadione The metabolism of Paramethadione can be decreased when combined with Ziprasidone. Approved Paramethasone The metabolism of Paramethasone can be decreased when combined with Ziprasidone. Approved Parecoxib The metabolism of Parecoxib can be decreased when combined with Ziprasidone. Approved Pargyline The metabolism of Ziprasidone can be decreased when combined with Pargyline. Approved Paricalcitol The metabolism of Paricalcitol can be decreased when combined with Ziprasidone. Approved, Investigational Paritaprevir The metabolism of Paritaprevir can be decreased when combined with Ziprasidone. Approved, Investigational Paroxetine Paroxetine may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Pasireotide Pasireotide may increase the QTc-prolonging activities of Ziprasidone. Approved Pazopanib Pazopanib may increase the QTc-prolonging activities of Ziprasidone. Approved Peginterferon alfa-2b The serum concentration of Ziprasidone can be increased when it is combined with Peginterferon alfa-2b. Approved Penbutolol Penbutolol may increase the orthostatic hypotensive activities of Ziprasidone. Approved, Investigational Penfluridol The risk or severity of adverse effects can be increased when Ziprasidone is combined with Penfluridol. Experimental Pentamidine Pentamidine may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Pentazocine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Pentazocine. Approved, Vet Approved Pentobarbital The metabolism of Ziprasidone can be increased when combined with Pentobarbital. Approved, Investigational, Vet Approved Pentoxifylline Pentoxifylline may increase the hypotensive activities of Ziprasidone. Approved, Investigational Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone. Approved Perazine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Perazine. Approved, Investigational Perflutren Perflutren may increase the QTc-prolonging activities of Ziprasidone. Approved Pergolide The risk or severity of adverse effects can be increased when Pergolide is combined with Ziprasidone. Approved, Investigational, Vet Approved, Withdrawn Perhexiline The metabolism of Perhexiline can be decreased when combined with Ziprasidone. Approved, Investigational Permethrin The metabolism of Permethrin can be decreased when combined with Ziprasidone. Approved, Investigational Perospirone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Perospirone. Approved Perphenazine The metabolism of Perphenazine can be decreased when combined with Ziprasidone. Approved Pethidine The metabolism of Pethidine can be decreased when combined with Ziprasidone. Approved Phenacetin The metabolism of Phenacetin can be decreased when combined with Ziprasidone. Withdrawn Phenazocine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Phenazocine. Experimental Phendimetrazine Ziprasidone may decrease the vasoconstricting activities of Phendimetrazine. Approved, Illicit Phenelzine The metabolism of Ziprasidone can be decreased when combined with Phenelzine. Approved Phenformin The metabolism of Phenformin can be decreased when combined with Ziprasidone. Approved, Investigational, Withdrawn Phenibut The risk or severity of adverse effects can be increased when Ziprasidone is combined with Phenibut. Experimental Pheniprazine The metabolism of Ziprasidone can be decreased when combined with Pheniprazine. Withdrawn Phenobarbital The metabolism of Ziprasidone can be increased when combined with Phenobarbital. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Phenoperidine. Experimental Phenoxybenzamine Ziprasidone may increase the antihypertensive activities of Phenoxybenzamine. Approved Phenoxyethanol The risk or severity of adverse effects can be increased when Ziprasidone is combined with Phenoxyethanol. Approved Phenoxypropazine The metabolism of Ziprasidone can be decreased when combined with Phenoxypropazine. Withdrawn Phenprocoumon The metabolism of Phenprocoumon can be decreased when combined with Ziprasidone. Approved, Investigational Phentermine Ziprasidone may decrease the stimulatory activities of Phentermine. Approved, Illicit Phentolamine Ziprasidone may increase the antihypertensive activities of Phentolamine. Approved Phenylephrine Ziprasidone may decrease the vasoconstricting activities of Phenylephrine. Approved Phenylpropanolamine Ziprasidone may decrease the vasoconstricting activities of Phenylpropanolamine. Approved, Vet Approved, Withdrawn Phenytoin The metabolism of Ziprasidone can be increased when combined with Phenytoin. Approved, Vet Approved Pilocarpine The metabolism of Pilocarpine can be decreased when combined with Ziprasidone. Approved, Investigational Pimecrolimus The metabolism of Pimecrolimus can be decreased when combined with Ziprasidone. Approved, Investigational Pimozide The serum concentration of Pimozide can be increased when it is combined with Ziprasidone. Approved Pinacidil The metabolism of Pinacidil can be decreased when combined with Ziprasidone. Approved Pinaverium The risk or severity of hypotension can be increased when Ziprasidone is combined with Pinaverium. Approved Pindolol Pindolol may increase the orthostatic hypotensive activities of Ziprasidone. Approved, Investigational Pioglitazone The metabolism of Pioglitazone can be decreased when combined with Ziprasidone. Approved, Investigational Pipamperone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Pipamperone. Approved, Investigational Piperaquine The metabolism of Piperaquine can be decreased when combined with Ziprasidone. Approved, Investigational Piperazine The metabolism of Piperazine can be decreased when combined with Ziprasidone. Approved, Vet Approved Pipotiazine The metabolism of Pipotiazine can be decreased when combined with Ziprasidone. Approved, Investigational Pirbuterol Ziprasidone may decrease the vasoconstricting activities of Pirbuterol. Approved Piribedil The therapeutic efficacy of Piribedil can be decreased when used in combination with Ziprasidone. Investigational Piritramide The risk or severity of adverse effects can be increased when Ziprasidone is combined with Piritramide. Approved, Investigational Pirlindole The metabolism of Ziprasidone can be decreased when combined with Pirlindole. Approved Pitavastatin The serum concentration of Pitavastatin can be increased when it is combined with Ziprasidone. Approved Pitolisant The serum concentration of Pitolisant can be increased when it is combined with Ziprasidone. Approved, Investigational Pivhydrazine The metabolism of Ziprasidone can be decreased when combined with Pivhydrazine. Withdrawn Pizotifen Ziprasidone may increase the antihypertensive activities of Pizotifen. Approved Platelet Activating Factor Platelet Activating Factor may increase the orthostatic hypotensive activities of Ziprasidone. Experimental Podofilox The metabolism of Podofilox can be decreased when combined with Ziprasidone. Approved Pomalidomide The metabolism of Pomalidomide can be decreased when combined with Ziprasidone. Approved Ponatinib The metabolism of Ponatinib can be decreased when combined with Ziprasidone. Approved, Investigational Posaconazole The metabolism of Ziprasidone can be decreased when combined with Posaconazole. Approved, Investigational, Vet Approved Practolol Practolol may increase the orthostatic hypotensive activities of Ziprasidone. Approved Pramipexole Ziprasidone may increase the sedative activities of Pramipexole. Approved, Investigational Pramlintide The therapeutic efficacy of Pramlintide can be decreased when used in combination with Ziprasidone. Approved, Investigational Pramocaine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Pramocaine. Approved Prasterone The metabolism of Prasterone can be decreased when combined with Ziprasidone. Approved, Investigational, Nutraceutical Prasugrel The metabolism of Prasugrel can be decreased when combined with Ziprasidone. Approved Pravastatin The serum concentration of Pravastatin can be increased when it is combined with Ziprasidone. Approved Prazepam The metabolism of Prazepam can be decreased when combined with Ziprasidone. Approved, Illicit Praziquantel The metabolism of Praziquantel can be decreased when combined with Ziprasidone. Approved, Investigational, Vet Approved Prazosin Prazosin may increase the antihypertensive activities of Ziprasidone. Approved Prednisolone The metabolism of Prednisolone can be decreased when combined with Ziprasidone. Approved, Vet Approved Prednisone The metabolism of Prednisone can be decreased when combined with Ziprasidone. Approved, Vet Approved Pregabalin The therapeutic efficacy of Ziprasidone can be increased when used in combination with Pregabalin. Approved, Illicit, Investigational Prenalterol Ziprasidone may decrease the vasoconstricting activities of Prenalterol. Experimental Prenylamine The risk or severity of hypotension can be increased when Ziprasidone is combined with Prenylamine. Withdrawn Prilocaine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Prilocaine. Approved Primaquine Primaquine may increase the QTc-prolonging activities of Ziprasidone. Approved Primidone The metabolism of Ziprasidone can be increased when combined with Primidone. Approved, Vet Approved Procainamide The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Procainamide. Approved Procaine The metabolism of Ziprasidone can be decreased when combined with Procaine. Approved, Investigational, Vet Approved Procarbazine The metabolism of Ziprasidone can be decreased when combined with Procarbazine. Approved, Investigational Procaterol Ziprasidone may decrease the vasoconstricting activities of Procaterol. Approved, Investigational Prochlorperazine The metabolism of Prochlorperazine can be decreased when combined with Ziprasidone. Approved, Vet Approved Progesterone The metabolism of Progesterone can be decreased when combined with Ziprasidone. Approved, Vet Approved Proguanil The metabolism of Proguanil can be decreased when combined with Ziprasidone. Approved Promazine Promazine may increase the QTc-prolonging activities of Ziprasidone. Approved, Vet Approved Promethazine Promethazine may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Propafenone The serum concentration of Ziprasidone can be increased when it is combined with Propafenone. Approved Propanidid The risk or severity of adverse effects can be increased when Ziprasidone is combined with Propanidid. Experimental Proparacaine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Proparacaine. Approved, Vet Approved Propericiazine Ziprasidone may increase the antihypertensive activities of Propericiazine. Approved, Investigational Propiomazine Ziprasidone may increase the antihypertensive activities of Propiomazine. Approved Propiverine Ziprasidone may increase the antihypertensive activities of Propiverine. Approved, Investigational Propofol Propofol may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Propoxycaine. Approved Propranolol Propranolol may increase the orthostatic hypotensive activities of Ziprasidone. Approved, Investigational Protokylol Ziprasidone may decrease the vasoconstricting activities of Protokylol. Approved, Vet Approved Protriptyline Protriptyline may increase the QTc-prolonging activities of Ziprasidone. Approved Proxibarbal The risk or severity of adverse effects can be increased when Ziprasidone is combined with Proxibarbal. Experimental PSD502 The risk or severity of adverse effects can be increased when Ziprasidone is combined with PSD502. Investigational Pseudoephedrine The metabolism of Pseudoephedrine can be decreased when combined with Ziprasidone. Approved Pyrazinamide The metabolism of Pyrazinamide can be decreased when combined with Ziprasidone. Approved, Investigational Quazepam The metabolism of Quazepam can be decreased when combined with Ziprasidone. Approved, Illicit Quetiapine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Quetiapine. Approved Quinacrine The metabolism of Quinacrine can be decreased when combined with Ziprasidone. Approved, Investigational Quinagolide The therapeutic efficacy of Quinagolide can be decreased when used in combination with Ziprasidone. Approved, Investigational Quinidine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Quinidine. Approved, Investigational Quinine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Quinine. Approved Quinisocaine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Quinisocaine. Experimental Rabeprazole The metabolism of Rabeprazole can be decreased when combined with Ziprasidone. Approved, Investigational Racepinephrine Ziprasidone may increase the antihypertensive activities of Racepinephrine. Approved Raclopride The risk or severity of adverse effects can be increased when Ziprasidone is combined with Raclopride. Investigational Ractopamine Ziprasidone may decrease the vasoconstricting activities of Ractopamine. Vet Approved Raloxifene The metabolism of Raloxifene can be decreased when combined with Ziprasidone. Approved, Investigational Ramelteon The metabolism of Ramelteon can be decreased when combined with Ziprasidone. Approved, Investigational Ranitidine The metabolism of Ranitidine can be decreased when combined with Ziprasidone. Approved Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Ziprasidone. Approved, Investigational Rasagiline The metabolism of Ziprasidone can be decreased when combined with Rasagiline. Approved Reboxetine The metabolism of Reboxetine can be decreased when combined with Ziprasidone. Approved, Investigational Regorafenib The metabolism of Regorafenib can be decreased when combined with Ziprasidone. Approved Remifentanil The risk or severity of adverse effects can be increased when Ziprasidone is combined with Remifentanil. Approved Remoxipride The metabolism of Remoxipride can be decreased when combined with Ziprasidone. Approved, Withdrawn Repaglinide The metabolism of Repaglinide can be decreased when combined with Ziprasidone. Approved, Investigational Repinotan The metabolism of Repinotan can be decreased when combined with Ziprasidone. Investigational Reproterol Ziprasidone may decrease the vasoconstricting activities of Reproterol. Investigational Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Ziprasidone. Approved, Investigational Retapamulin The metabolism of Retapamulin can be decreased when combined with Ziprasidone. Approved Rifabutin The metabolism of Ziprasidone can be increased when combined with Rifabutin. Approved, Investigational Rifampicin The metabolism of Ziprasidone can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Ziprasidone can be increased when combined with Rifapentine. Approved, Investigational Rilmenidine Ziprasidone may decrease the vasoconstricting activities of Rilmenidine. Approved, Investigational Rilpivirine The serum concentration of Rilpivirine can be increased when it is combined with Ziprasidone. Approved Rimiterol Ziprasidone may decrease the vasoconstricting activities of Rimiterol. Experimental Rimonabant The metabolism of Rimonabant can be decreased when combined with Ziprasidone. Approved, Investigational Riociguat The metabolism of Riociguat can be decreased when combined with Ziprasidone. Approved Risperidone Ziprasidone may increase the antihypertensive activities of Risperidone. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Ziprasidone is combined with Ritanserin. Investigational Ritobegron Ziprasidone may decrease the stimulatory activities of Ritobegron. Investigational Ritodrine Ziprasidone may decrease the vasoconstricting activities of Ritodrine. Approved, Investigational Ritonavir Ritonavir may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Rivaroxaban The metabolism of Rivaroxaban can be decreased when combined with Ziprasidone. Approved Rizatriptan The risk or severity of adverse effects can be increased when Rizatriptan is combined with Ziprasidone. Approved Rofecoxib The metabolism of Rofecoxib can be decreased when combined with Ziprasidone. Approved, Investigational, Withdrawn Rolapitant The metabolism of Rolapitant can be decreased when combined with Ziprasidone. Approved, Investigational Romidepsin The metabolism of Romidepsin can be decreased when combined with Ziprasidone. Approved, Investigational Romifidine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Romifidine. Vet Approved Ropinirole Ziprasidone may increase the sedative activities of Ropinirole. Approved, Investigational Ropivacaine The metabolism of Ropivacaine can be decreased when combined with Ziprasidone. Approved Rosiglitazone The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Ziprasidone. Approved, Investigational Rosuvastatin The serum concentration of Rosuvastatin can be increased when it is combined with Ziprasidone. Approved Rotigotine Ziprasidone may increase the sedative activities of Rotigotine. Approved Roxithromycin The metabolism of Roxithromycin can be decreased when combined with Ziprasidone. Approved, Investigational, Withdrawn Rucaparib The metabolism of Rucaparib can be decreased when combined with Ziprasidone. Approved, Investigational Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Ziprasidone. Approved Rupatadine The metabolism of Rupatadine can be decreased when combined with Ziprasidone. Approved Ruxolitinib The metabolism of Ruxolitinib can be decreased when combined with Ziprasidone. Approved Safinamide The metabolism of Safinamide can be decreased when combined with Ziprasidone. Approved, Investigational Safrazine The metabolism of Ziprasidone can be decreased when combined with Safrazine. Withdrawn Salbutamol Salbutamol may increase the QTc-prolonging activities of Ziprasidone. Approved, Vet Approved Salmeterol The serum concentration of Salmeterol can be increased when it is combined with Ziprasidone. Approved Saquinavir Saquinavir may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Sarilumab The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Sarilumab. Approved, Investigational Saxagliptin The serum concentration of Saxagliptin can be increased when it is combined with Ziprasidone. Approved Scopolamine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Scopolamine. Approved, Investigational Secobarbital The risk or severity of adverse effects can be increased when Ziprasidone is combined with Secobarbital. Approved, Vet Approved Selegiline The metabolism of Ziprasidone can be decreased when combined with Selegiline. Approved, Investigational, Vet Approved Seletracetam The risk or severity of hypotension can be increased when Ziprasidone is combined with Seletracetam. Investigational Selexipag The metabolism of Selexipag can be decreased when combined with Ziprasidone. Approved Sepranolone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Sepranolone. Investigational Seratrodast The metabolism of Seratrodast can be decreased when combined with Ziprasidone. Approved Sertindole The metabolism of Sertindole can be decreased when combined with Ziprasidone. Approved, Investigational, Withdrawn Sertraline Sertraline may increase the QTc-prolonging activities of Ziprasidone. Approved Sevoflurane Sevoflurane may increase the QTc-prolonging activities of Ziprasidone. Approved, Vet Approved Sibutramine The metabolism of Sibutramine can be decreased when combined with Ziprasidone. Approved, Illicit, Investigational, Withdrawn Sildenafil Sildenafil may increase the hypotensive activities of Ziprasidone. Approved, Investigational Silodosin Silodosin may increase the antihypertensive activities of Ziprasidone. Approved Siltuximab The serum concentration of Ziprasidone can be decreased when it is combined with Siltuximab. Approved, Investigational Simeprevir The serum concentration of Ziprasidone can be increased when it is combined with Simeprevir. Approved Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Ziprasidone. Approved Sirolimus The metabolism of Sirolimus can be decreased when combined with Ziprasidone. Approved, Investigational Sitagliptin The metabolism of Sitagliptin can be decreased when combined with Ziprasidone. Approved, Investigational Sodium oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone. Approved Solabegron Ziprasidone may decrease the vasoconstricting activities of Solabegron. Investigational Solifenacin Solifenacin may increase the QTc-prolonging activities of Ziprasidone. Approved Sonidegib The serum concentration of Sonidegib can be increased when it is combined with Ziprasidone. Approved, Investigational Sorafenib Sorafenib may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Sotagliflozin The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Ziprasidone. Investigational Sotalol The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Sotalol. Approved Sparteine The metabolism of Sparteine can be decreased when combined with Ziprasidone. Experimental Spiramycin The metabolism of Spiramycin can be decreased when combined with Ziprasidone. Approved St. John's Wort The serum concentration of Ziprasidone can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stiripentol The serum concentration of Ziprasidone can be increased when it is combined with Stiripentol. Approved Sufentanil The metabolism of Sufentanil can be decreased when combined with Ziprasidone. Approved, Investigational Sulfadiazine The metabolism of Sulfadiazine can be decreased when combined with Ziprasidone. Approved, Investigational, Vet Approved Sulfamethoxazole Sulfamethoxazole may increase the QTc-prolonging activities of Ziprasidone. Approved Sulfinpyrazone The metabolism of Sulfinpyrazone can be decreased when combined with Ziprasidone. Approved Sulfisoxazole Sulfisoxazole may increase the QTc-prolonging activities of Ziprasidone. Approved, Vet Approved Sulodexide The therapeutic efficacy of Sulodexide can be decreased when used in combination with Ziprasidone. Approved, Investigational Sulpiride Ziprasidone may increase the antipsychotic activities of Sulpiride. Approved, Investigational Sultopride The risk or severity of adverse effects can be increased when Ziprasidone is combined with Sultopride. Experimental Sumatriptan The risk or severity of adverse effects can be increased when Sumatriptan is combined with Ziprasidone. Approved, Investigational Sunitinib Sunitinib may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Suvorexant Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved, Investigational Synephrine Ziprasidone may decrease the vasoconstricting activities of Synephrine. Experimental Synthetic Conjugated Estrogens, A The metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Ziprasidone. Approved Synthetic Conjugated Estrogens, B The metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Ziprasidone. Approved Tacrolimus The metabolism of Tacrolimus can be decreased when combined with Ziprasidone. Approved, Investigational Tadalafil Tadalafil may increase the hypotensive activities of Ziprasidone. Approved, Investigational Talinolol Talinolol may increase the orthostatic hypotensive activities of Ziprasidone. Investigational Tamoxifen The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Ziprasidone resulting in a loss in efficacy. Approved Tamsulosin Tamsulosin may increase the antihypertensive activities of Ziprasidone. Approved, Investigational Tandospirone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone. Approved Tasimelteon The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tasimelteon. Approved, Investigational Tasosartan The metabolism of Tasosartan can be decreased when combined with Ziprasidone. Approved Taurochenodeoxycholic acid The metabolism of Taurochenodeoxycholic acid can be decreased when combined with Ziprasidone. Experimental Tedizolid Phosphate The risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Ziprasidone. Approved Tegaserod The metabolism of Tegaserod can be decreased when combined with Ziprasidone. Approved, Investigational, Withdrawn Telaprevir The metabolism of Ziprasidone can be decreased when combined with Telaprevir. Approved, Withdrawn Telavancin Telavancin may increase the QTc-prolonging activities of Ziprasidone. Approved Telithromycin Telithromycin may increase the QTc-prolonging activities of Ziprasidone. Approved Temazepam The metabolism of Temazepam can be decreased when combined with Ziprasidone. Approved, Investigational Temsirolimus The metabolism of Temsirolimus can be decreased when combined with Ziprasidone. Approved Teniposide The metabolism of Teniposide can be decreased when combined with Ziprasidone. Approved Tenofovir disoproxil The metabolism of Ziprasidone can be decreased when combined with Tenofovir disoproxil. Approved, Investigational Terazosin Terazosin may increase the antihypertensive activities of Ziprasidone. Approved Terbinafine The metabolism of Terbinafine can be decreased when combined with Ziprasidone. Approved, Investigational, Vet Approved Terbutaline Terbutaline may increase the QTc-prolonging activities of Ziprasidone. Approved Terfenadine The metabolism of Terfenadine can be decreased when combined with Ziprasidone. Approved, Withdrawn Terguride The risk or severity of adverse effects can be increased when Terguride is combined with Ziprasidone. Experimental Teriflunomide The serum concentration of Ziprasidone can be decreased when it is combined with Teriflunomide. Approved Terodiline The risk or severity of hypotension can be increased when Ziprasidone is combined with Terodiline. Experimental Tertatolol Tertatolol may increase the orthostatic hypotensive activities of Ziprasidone. Experimental Tesmilifene The metabolism of Tesmilifene can be decreased when combined with Ziprasidone. Investigational Testosterone The metabolism of Testosterone can be decreased when combined with Ziprasidone. Approved, Investigational Testosterone cypionate The metabolism of Testosterone cypionate can be decreased when combined with Ziprasidone. Approved Testosterone enanthate The metabolism of Testosterone enanthate can be decreased when combined with Ziprasidone. Approved Testosterone propionate The metabolism of Testosterone propionate can be decreased when combined with Ziprasidone. Approved, Investigational, Vet Approved, Withdrawn Testosterone undecanoate The metabolism of Testosterone undecanoate can be decreased when combined with Ziprasidone. Approved, Investigational Tetrabenazine The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Ziprasidone. Approved, Investigational Tetracaine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tetracaine. Approved, Vet Approved Tetracycline The metabolism of Tetracycline can be decreased when combined with Ziprasidone. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tetrahydropalmatine. Investigational Tetrodotoxin The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tetrodotoxin. Investigational Tetryzoline Ziprasidone may decrease the vasoconstricting activities of Tetryzoline. Approved Tezacaftor The metabolism of Tezacaftor can be decreased when combined with Ziprasidone. Approved, Investigational Thalidomide Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Theophylline Theophylline may increase the hypotensive activities of Ziprasidone. Approved Thiamylal The risk or severity of adverse effects can be increased when Ziprasidone is combined with Thiamylal. Approved, Vet Approved Thiopental The risk or severity of adverse effects can be increased when Ziprasidone is combined with Thiopental. Approved, Vet Approved Thioproperazine Ziprasidone may increase the antihypertensive activities of Thioproperazine. Approved Thioridazine The serum concentration of Thioridazine can be increased when it is combined with Ziprasidone. Approved, Withdrawn Thiotepa The metabolism of Thiotepa can be decreased when combined with Ziprasidone. Approved, Investigational Thiothixene Thiothixene may increase the QTc-prolonging activities of Ziprasidone. Approved Tiagabine The metabolism of Tiagabine can be decreased when combined with Ziprasidone. Approved, Investigational Tiapride The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tiapride. Approved, Investigational Ticagrelor The metabolism of Ticagrelor can be decreased when combined with Ziprasidone. Approved Ticlopidine The metabolism of Ziprasidone can be decreased when combined with Ticlopidine. Approved Tiletamine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tiletamine. Vet Approved Tilidine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tilidine. Experimental Timolol Timolol may increase the orthostatic hypotensive activities of Ziprasidone. Approved Tinidazole The metabolism of Tinidazole can be decreased when combined with Ziprasidone. Approved, Investigational Tiotropium The metabolism of Tiotropium can be decreased when combined with Ziprasidone. Approved Tipranavir The metabolism of Tipranavir can be decreased when combined with Ziprasidone. Approved, Investigational Tizanidine Tizanidine may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Tocilizumab The serum concentration of Ziprasidone can be decreased when it is combined with Tocilizumab. Approved Tocofersolan The metabolism of Tocofersolan can be decreased when combined with Ziprasidone. Approved Tocopherol The metabolism of Tocopherol can be decreased when combined with Ziprasidone. Approved, Investigational Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Ziprasidone. Approved, Investigational Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Ziprasidone. Approved, Investigational Tolazoline Ziprasidone may increase the antihypertensive activities of Tolazoline. Approved, Vet Approved Tolbutamide The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Ziprasidone. Approved, Investigational Tolcapone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tolcapone. Approved, Withdrawn Tolfenamic Acid The risk or severity of hypotension can be increased when Ziprasidone is combined with Tolfenamic Acid. Approved, Investigational Toloxatone The metabolism of Ziprasidone can be decreased when combined with Toloxatone. Approved Tolterodine Tolterodine may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Ziprasidone. Approved Topiramate The risk or severity of adverse effects can be increased when Ziprasidone is combined with Topiramate. Approved Toremifene The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Toremifene. Approved, Investigational Trabectedin The metabolism of Trabectedin can be decreased when combined with Ziprasidone. Approved, Investigational Tramadol The therapeutic efficacy of Tramadol can be decreased when used in combination with Ziprasidone. Approved, Investigational Tranilast The risk or severity of hypotension can be increased when Ziprasidone is combined with Tranilast. Approved, Investigational Tranylcypromine The metabolism of Ziprasidone can be decreased when combined with Tranylcypromine. Approved, Investigational Trastuzumab emtansine The metabolism of Trastuzumab emtansine can be decreased when combined with Ziprasidone. Approved, Investigational Trazodone Ziprasidone may increase the antihypertensive activities of Trazodone. Approved, Investigational Treprostinil Treprostinil may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Tretinoin The metabolism of Tretinoin can be decreased when combined with Ziprasidone. Approved, Investigational, Nutraceutical Tretoquinol Ziprasidone may decrease the vasoconstricting activities of Tretoquinol. Experimental Triamcinolone The metabolism of Triamcinolone can be decreased when combined with Ziprasidone. Approved, Vet Approved Triazolam The metabolism of Triazolam can be decreased when combined with Ziprasidone. Approved, Investigational Tricaine methanesulfonate The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tricaine methanesulfonate. Vet Approved Trichloroethylene The risk or severity of adverse effects can be increased when Ziprasidone is combined with Trichloroethylene. Approved Trifluoperazine Ziprasidone may increase the antihypertensive activities of Trifluoperazine. Approved, Investigational Trifluperidol The risk or severity of adverse effects can be increased when Ziprasidone is combined with Trifluperidol. Experimental Triflupromazine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Triflupromazine. Approved, Vet Approved Trimazosin Trimazosin may increase the antihypertensive activities of Ziprasidone. Experimental Trimebutine The risk or severity of hypotension can be increased when Ziprasidone is combined with Trimebutine. Approved Trimethadione The metabolism of Trimethadione can be decreased when combined with Ziprasidone. Approved Trimethoprim Trimethoprim may increase the QTc-prolonging activities of Ziprasidone. Approved, Vet Approved Trimipramine Ziprasidone may increase the antihypertensive activities of Trimipramine. Approved Triprolidine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Triprolidine. Approved Triptorelin Triptorelin may increase the QTc-prolonging activities of Ziprasidone. Approved, Vet Approved Troglitazone The metabolism of Troglitazone can be decreased when combined with Ziprasidone. Investigational, Withdrawn Troleandomycin The metabolism of Troleandomycin can be decreased when combined with Ziprasidone. Approved Tulobuterol Ziprasidone may decrease the vasoconstricting activities of Tulobuterol. Investigational Udenafil Udenafil may increase the hypotensive activities of Ziprasidone. Approved, Investigational Ulipristal The serum concentration of Ulipristal can be increased when it is combined with Ziprasidone. Approved Umeclidinium The metabolism of Umeclidinium can be decreased when combined with Ziprasidone. Approved Urapidil Urapidil may increase the antihypertensive activities of Ziprasidone. Investigational Valbenazine The metabolism of Valbenazine can be decreased when combined with Ziprasidone. Approved, Investigational Valdecoxib The metabolism of Valdecoxib can be decreased when combined with Ziprasidone. Approved, Investigational, Withdrawn Valproic Acid The risk or severity of adverse effects can be increased when Ziprasidone is combined with Valproic Acid. Approved, Investigational Vandetanib The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Vandetanib. Approved Vanoxerine The metabolism of Vanoxerine can be decreased when combined with Ziprasidone. Investigational Vardenafil Vardenafil may increase the QTc-prolonging activities of Ziprasidone. Approved Velpatasvir The metabolism of Velpatasvir can be decreased when combined with Ziprasidone. Approved, Investigational Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ziprasidone. Approved Venetoclax The metabolism of Venetoclax can be decreased when combined with Ziprasidone. Approved, Investigational Venlafaxine Venlafaxine may increase the QTc-prolonging activities of Ziprasidone. Approved Veralipride The risk or severity of adverse effects can be increased when Ziprasidone is combined with Veralipride. Experimental Verapamil Ziprasidone may increase the antihypertensive activities of Verapamil. Approved Vernakalant The metabolism of Vernakalant can be decreased when combined with Ziprasidone. Approved, Investigational Vicriviroc The metabolism of Vicriviroc can be decreased when combined with Ziprasidone. Investigational Vigabatrin The risk or severity of adverse effects can be increased when Ziprasidone is combined with Vigabatrin. Approved Vilanterol Vilanterol may increase the QTc-prolonging activities of Ziprasidone. Approved Vilazodone The serum concentration of Vilazodone can be increased when it is combined with Ziprasidone. Approved Vildagliptin The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Ziprasidone. Approved, Investigational Vinblastine The metabolism of Vinblastine can be decreased when combined with Ziprasidone. Approved Vincristine The metabolism of Vincristine can be decreased when combined with Ziprasidone. Approved, Investigational Vindesine The serum concentration of Vindesine can be increased when it is combined with Ziprasidone. Approved, Investigational Vinflunine The metabolism of Vinflunine can be decreased when combined with Ziprasidone. Approved, Investigational Vinorelbine The metabolism of Vinorelbine can be decreased when combined with Ziprasidone. Approved, Investigational Vinpocetine The risk or severity of hypotension can be increased when Ziprasidone is combined with Vinpocetine. Investigational Vinyl ether The risk or severity of adverse effects can be increased when Ziprasidone is combined with Vinyl ether. Experimental Vismodegib The metabolism of Vismodegib can be decreased when combined with Ziprasidone. Approved, Investigational Voglibose The therapeutic efficacy of Voglibose can be decreased when used in combination with Ziprasidone. Approved, Investigational Voriconazole The metabolism of Ziprasidone can be decreased when combined with Voriconazole. Approved, Investigational Vorinostat Vorinostat may increase the QTc-prolonging activities of Ziprasidone. Approved, Investigational Vortioxetine The metabolism of Vortioxetine can be decreased when combined with Ziprasidone. Approved, Investigational Voxilaprevir The metabolism of Voxilaprevir can be decreased when combined with Ziprasidone. Approved, Investigational Warfarin The metabolism of Warfarin can be decreased when combined with Ziprasidone. Approved WIN 55212-2 The risk or severity of hypotension can be increased when Ziprasidone is combined with WIN 55212-2. Experimental Xamoterol Ziprasidone may decrease the vasoconstricting activities of Xamoterol. Experimental Xenon The risk or severity of adverse effects can be increased when Ziprasidone is combined with Xenon. Experimental Xylazine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Xylazine. Vet Approved Xylometazoline Ziprasidone may decrease the vasoconstricting activities of Xylometazoline. Approved, Investigational Yohimbine The metabolism of Yohimbine can be decreased when combined with Ziprasidone. Approved, Investigational, Vet Approved Zafirlukast The metabolism of Zafirlukast can be decreased when combined with Ziprasidone. Approved, Investigational Zalcitabine The metabolism of Zalcitabine can be decreased when combined with Ziprasidone. Approved, Investigational Zaleplon The metabolism of Zaleplon can be decreased when combined with Ziprasidone. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Ziprasidone is combined with Ziconotide. Approved Zidovudine The metabolism of Zidovudine can be decreased when combined with Ziprasidone. Approved Zileuton The metabolism of Zileuton can be decreased when combined with Ziprasidone. Approved, Investigational, Withdrawn Zimelidine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Zimelidine. Withdrawn Zolazepam The risk or severity of adverse effects can be increased when Ziprasidone is combined with Zolazepam. Vet Approved Zolmitriptan The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Ziprasidone. Approved, Investigational Zolpidem Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zomepirac The metabolism of Zomepirac can be decreased when combined with Ziprasidone. Withdrawn Zonisamide The metabolism of Zonisamide can be decreased when combined with Ziprasidone. Approved, Investigational Zopiclone The serum concentration of Zopiclone can be increased when it is combined with Ziprasidone. Approved Zotepine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Zotepine. Approved, Investigational, Withdrawn Zucapsaicin The metabolism of Ziprasidone can be decreased when combined with Zucapsaicin. Approved, Investigational Zuclopenthixol The serum concentration of Zuclopenthixol can be increased when it is combined with Ziprasidone. Approved, Investigational - Food Interactions
- Avoid alcohol.
References
- Synthesis Reference
Frank R. Busch, Carol A. Rose, "Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist." U.S. Patent US6110918, issued January, 1995.
US6110918- General References
- Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 Suppl 19:6-12. [PubMed:14728084]
- Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH: Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001 Aug 17;425(3):197-201. [PubMed:11513838]
- External Links
- Human Metabolome Database
- HMDB0014391
- KEGG Compound
- C07568
- PubChem Compound
- 60854
- PubChem Substance
- 46507627
- ChemSpider
- 54841
- BindingDB
- 50048803
- ChEBI
- 10119
- ChEMBL
- CHEMBL708
- Therapeutic Targets Database
- DAP000079
- PharmGKB
- PA451974
- IUPHAR
- 59
- Guide to Pharmacology
- GtP Drug Page
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Ziprasidone
- ATC Codes
- N05AE04 — Ziprasidone
- AHFS Codes
- 28:16.08.04 — Atypical Antipsychotics
- FDA label
- Download (75 KB)
- MSDS
- Download (57.8 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Pfizer inc
- Packagers
- Ben Venue Laboratories Inc.
- Cardinal Health
- Comprehensive Consultant Services Inc.
- Kaiser Foundation Hospital
- Lake Erie Medical and Surgical Supply
- Nucare Pharmaceuticals Inc.
- Pfizer Inc.
- Pharmacia Inc.
- Physicians Total Care Inc.
- Prepackage Specialists
- Rebel Distributors Corp.
- Remedy Repack
- Resource Optimization and Innovation LLC
- Stat Rx Usa
- US Pharmaceutical Group
- Dosage forms
Form Route Strength Capsule Oral 20 mg Capsule Oral 20 mg/1 Capsule Oral 40 mg/1 Capsule Oral 60 mg/1 Capsule Oral 80 mg/1 Injection, powder, lyophilized, for solution Intramuscular 20 mg/mL Capsule Oral 20.0 mg Capsule Oral 40 mg Capsule Oral 60 mg Capsule Oral 80 mg - Prices
Unit description Cost Unit Zoladex 10.8 mg Implant Syringe 1407.72USD syringe Geodon 20 mg vial 16.22USD vial Geodon 60 mg capsule 9.88USD capsule Geodon 80 mg capsule 9.88USD capsule Geodon 20 mg capsule 8.14USD capsule Geodon 40 mg capsule 8.14USD capsule Zeldox 40 mg Capsule 2.13USD capsule Zeldox 60 mg Capsule 2.13USD capsule Zeldox 80 mg Capsule 2.13USD capsule Zeldox 20 mg Capsule 1.86USD capsule DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US5134127 No 1993-01-23 2010-01-23 US CA2256227 No 2003-07-01 2018-12-16 Canada CA2105114 No 2000-02-15 2013-08-30 Canada US6245766 No 1998-12-18 2018-12-18 US US6150366 No 1999-05-27 2019-05-27 US US6232304 No 1997-04-01 2017-04-01 US US6399777 No 1997-04-01 2017-04-01 US US6110918 No 1997-03-26 2017-03-26 US US7175855 No 2000-05-18 2020-05-18 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) >300 °C Not Available logP 3.8 Not Available - Predicted Properties
Property Value Source Water Solubility 0.00718 mg/mL ALOGPS logP 4.64 ALOGPS logP 4.3 ChemAxon logS -4.8 ALOGPS pKa (Strongest Acidic) 13.18 ChemAxon pKa (Strongest Basic) 7.09 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 48.47 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 116.72 m3·mol-1 ChemAxon Polarizability 44.96 Å3 ChemAxon Number of Rings 5 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9759 Caco-2 permeable + 0.8867 P-glycoprotein substrate Substrate 0.7167 P-glycoprotein inhibitor I Inhibitor 0.8052 P-glycoprotein inhibitor II Inhibitor 0.6419 Renal organic cation transporter Inhibitor 0.5325 CYP450 2C9 substrate Non-substrate 0.7972 CYP450 2D6 substrate Non-substrate 0.9117 CYP450 3A4 substrate Substrate 0.7408 CYP450 1A2 substrate Inhibitor 0.6576 CYP450 2C9 inhibitor Inhibitor 0.6329 CYP450 2D6 inhibitor Non-inhibitor 0.7151 CYP450 2C19 inhibitor Inhibitor 0.8086 CYP450 3A4 inhibitor Non-inhibitor 0.7723 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.9567 Ames test Non AMES toxic 0.6273 Carcinogenicity Non-carcinogens 0.8672 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.5877 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.6826 hERG inhibition (predictor II) Inhibitor 0.7753
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-QFT , positive LC-MS/MS splash10-01ox-0900400000-0a17dd0e237f50ba91c5
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazinanes
- Sub Class
- Piperazines
- Direct Parent
- N-arylpiperazines
- Alternative Parents
- Benzothiazoles / Phenethylamines / Indoles / Dialkylarylamines / Aralkylamines / N-alkylpiperazines / Aminothiazoles / Aryl chlorides / Imidolactams / Heteroaromatic compounds show 8 more
- Substituents
- N-arylpiperazine / 1,2-benzothiazole / Indole / Indole or derivatives / Phenethylamine / Dialkylarylamine / N-alkylpiperazine / Aralkylamine / Imidolactam / Benzenoid show 22 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- organochlorine compound, indolones, piperazines, 1,2-benzisothiazole (CHEBI:10119)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Potassium channel regulator activity
- Specific Function
- Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
- Gene Name
- DRD2
- Uniprot ID
- P14416
- Uniprot Name
- D(2) dopamine receptor
- Molecular Weight
- 50618.91 Da
References
- Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706]
- Kopecek M, Bares M, Mohr P: Ziprasidone-induced galactorrhea: a case report. Neuro Endocrinol Lett. 2005 Feb;26(1):69-70. [PubMed:15726024]
- Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA 3rd, et al.: Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995 Oct;275(1):101-13. [PubMed:7562537]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 Suppl 19:6-12. [PubMed:14728084]
- Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Virus receptor activity
- Specific Function
- G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
- Gene Name
- HTR2A
- Uniprot ID
- P28223
- Uniprot Name
- 5-hydroxytryptamine receptor 2A
- Molecular Weight
- 52602.58 Da
References
- Mansbach RS, Carver J, Zorn SH: Blockade of drug-induced deficits in prepulse inhibition of acoustic startle by ziprasidone. Pharmacol Biochem Behav. 2001 Jul-Aug;69(3-4):535-42. [PubMed:11509214]
- Ichikawa J, Li Z, Dai J, Meltzer HY: Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res. 2002 Nov 29;956(2):349-57. [PubMed:12445705]
- Lu BY, Lundgren R, Escalona PR, Roberts BB: A case of ziprasidone-induced mania and the role of 5-HT2A in mood changes induced by atypical antipsychotics. J Clin Psychiatry. 2002 Dec;63(12):1185-6. [PubMed:12530423]
- Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G: A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004 May;161(5):818-25. [PubMed:15121646]
- Kast RE, Focosi D, Petrini M, Altschuler EL: Treatment schedules for 5-HT2A blocking in progressive multifocal leukoencephalopathy using risperidone or ziprasidone. Bone Marrow Transplant. 2007 Jun;39(12):811-2. Epub 2007 Apr 23. [PubMed:17450180]
- Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 Suppl 19:6-12. [PubMed:14728084]
- Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- G-protein coupled amine receptor activity
- Specific Function
- Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
- Gene Name
- DRD1
- Uniprot ID
- P21728
- Uniprot Name
- D(1A) dopamine receptor
- Molecular Weight
- 49292.765 Da
References
- Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- G-protein coupled amine receptor activity
- Specific Function
- Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
- Gene Name
- DRD5
- Uniprot ID
- P21918
- Uniprot Name
- D(1B) dopamine receptor
- Molecular Weight
- 52950.5 Da
References
- Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- G-protein coupled amine receptor activity
- Specific Function
- Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
- Gene Name
- DRD3
- Uniprot ID
- P35462
- Uniprot Name
- D(3) dopamine receptor
- Molecular Weight
- 44224.335 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Sh3 domain binding
- Specific Function
- Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
- Gene Name
- DRD4
- Uniprot ID
- P21917
- Uniprot Name
- D(4) dopamine receptor
- Molecular Weight
- 48359.86 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Agonist
- General Function
- Serotonin receptor activity
- Specific Function
- G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
- Gene Name
- HTR1A
- Uniprot ID
- P08908
- Uniprot Name
- 5-hydroxytryptamine receptor 1A
- Molecular Weight
- 46106.335 Da
References
- Sprouse JS, Reynolds LS, Braselton JP, Rollema H, Zorn SH: Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation. Neuropsychopharmacology. 1999 Nov;21(5):622-31. [PubMed:10516958]
- Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH: 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry. 2000 Aug 1;48(3):229-37. [PubMed:10924666]
- Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
- Wilner KD, Anziano RJ, Johnson AC, Miceli JJ, Fricke JR, Titus CK: The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery. J Clin Psychopharmacol. 2002 Apr;22(2):206-10. [PubMed:11910268]
- Newman-Tancredi A, Rivet JM, Cussac D, Touzard M, Chaput C, Marini L, Millan MJ: Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924. Naunyn Schmiedebergs Arch Pharmacol. 2003 Sep;368(3):188-99. Epub 2003 Aug 16. [PubMed:12923612]
- Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 Suppl 19:6-12. [PubMed:14728084]
- Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH: Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001 Aug 17;425(3):197-201. [PubMed:11513838]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Serotonin receptor activity
- Specific Function
- G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
- Gene Name
- HTR1B
- Uniprot ID
- P28222
- Uniprot Name
- 5-hydroxytryptamine receptor 1B
- Molecular Weight
- 43567.535 Da
References
- Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Serotonin receptor activity
- Specific Function
- G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
- Gene Name
- HTR1D
- Uniprot ID
- P28221
- Uniprot Name
- 5-hydroxytryptamine receptor 1D
- Molecular Weight
- 41906.38 Da
References
- Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 Suppl 19:6-12. [PubMed:14728084]
- Wilner KD, Anziano RJ, Johnson AC, Miceli JJ, Fricke JR, Titus CK: The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery. J Clin Psychopharmacol. 2002 Apr;22(2):206-10. [PubMed:11910268]
- Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA 3rd, et al.: Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995 Oct;275(1):101-13. [PubMed:7562537]
- Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
- Sprouse JS, Reynolds LS, Braselton JP, Rollema H, Zorn SH: Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation. Neuropsychopharmacology. 1999 Nov;21(5):622-31. [PubMed:10516958]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Serotonin receptor activity
- Specific Function
- G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that trig...
- Gene Name
- HTR1E
- Uniprot ID
- P28566
- Uniprot Name
- 5-hydroxytryptamine receptor 1E
- Molecular Weight
- 41681.57 Da
References
- Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Serotonin receptor activity
- Specific Function
- G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
- Gene Name
- HTR2C
- Uniprot ID
- P28335
- Uniprot Name
- 5-hydroxytryptamine receptor 2C
- Molecular Weight
- 51820.705 Da
References
- Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 Suppl 19:6-12. [PubMed:14728084]
- Sanchez C, Arnt J: In-vivo assessment of 5-HT2A and 5-HT2C antagonistic properties of newer antipsychotics. Behav Pharmacol. 2000 Jun;11(3-4):291-8. [PubMed:11103883]
- Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA 3rd, et al.: Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995 Oct;275(1):101-13. [PubMed:7562537]
- Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
- Wood MD, Scott C, Clarke K, Cato KJ, Patel N, Heath J, Worby A, Gordon L, Campbell L, Riley G, Davies CH, Gribble A, Jones DN: Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade. CNS Neurol Disord Drug Targets. 2006 Aug;5(4):445-52. [PubMed:16918396]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Voltage-gated potassium channel activity
- Specific Function
- This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
- Gene Name
- HTR3A
- Uniprot ID
- P46098
- Uniprot Name
- 5-hydroxytryptamine receptor 3A
- Molecular Weight
- 55279.835 Da
References
- Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Serotonin receptor activity
- Specific Function
- This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
- Gene Name
- HTR6
- Uniprot ID
- P50406
- Uniprot Name
- 5-hydroxytryptamine receptor 6
- Molecular Weight
- 46953.625 Da
References
- Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Serotonin receptor activity
- Specific Function
- This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
- Gene Name
- HTR7
- Uniprot ID
- P34969
- Uniprot Name
- 5-hydroxytryptamine receptor 7
- Molecular Weight
- 53554.43 Da
References
- Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, Molski TF, Yocca FD, Sharp T, Kikuchi T, Burris KD: Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl). 2007 Feb;190(3):373-82. Epub 2006 Nov 25. [PubMed:17242925]
- Meltzer HY: The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 1999 Aug;21(2 Suppl):106S-115S. [PubMed:10432496]
- Meltzer HY: Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci. 1995;3(2):64-75. [PubMed:7583621]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- Antagonist
- General Function
- Histamine receptor activity
- Specific Function
- In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
- Gene Name
- HRH1
- Uniprot ID
- P35367
- Uniprot Name
- Histamine H1 receptor
- Molecular Weight
- 55783.61 Da
References
- Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
- Arnt J: Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur J Pharmacol. 1995 Sep 5;283(1-3):55-62. [PubMed:7498321]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- Antagonist
- General Function
- Protein heterodimerization activity
- Specific Function
- This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
- Gene Name
- ADRA1A
- Uniprot ID
- P35348
- Uniprot Name
- Alpha-1A adrenergic receptor
- Molecular Weight
- 51486.005 Da
References
- Andersohn F, Schmedt N, Weinmann S, Willich SN, Garbe E: Priapism associated with antipsychotics: role of alpha1 adrenoceptor affinity. J Clin Psychopharmacol. 2010 Feb;30(1):68-71. doi: 10.1097/JCP.0b013e3181c8273d. [PubMed:20075651]
- Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- Antagonist
- General Function
- Protein heterodimerization activity
- Specific Function
- This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
- Gene Name
- ADRA1B
- Uniprot ID
- P35368
- Uniprot Name
- Alpha-1B adrenergic receptor
- Molecular Weight
- 56835.375 Da
References
- Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- Antagonist
- General Function
- Thioesterase binding
- Specific Function
- Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
- Gene Name
- ADRA2A
- Uniprot ID
- P08913
- Uniprot Name
- Alpha-2A adrenergic receptor
- Molecular Weight
- 48956.275 Da
References
- Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- Antagonist
- General Function
- Epinephrine binding
- Specific Function
- Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
- Gene Name
- ADRA2B
- Uniprot ID
- P18089
- Uniprot Name
- Alpha-2B adrenergic receptor
- Molecular Weight
- 49565.8 Da
References
- Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- Antagonist
- General Function
- Protein homodimerization activity
- Specific Function
- Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
- Gene Name
- ADRA2C
- Uniprot ID
- P18825
- Uniprot Name
- Alpha-2C adrenergic receptor
- Molecular Weight
- 49521.585 Da
References
- Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- Antagonist
- General Function
- Phosphatidylinositol phospholipase c activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM1
- Uniprot ID
- P11229
- Uniprot Name
- Muscarinic acetylcholine receptor M1
- Molecular Weight
- 51420.375 Da
References
- Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- Antagonist
- General Function
- G-protein coupled acetylcholine receptor activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM2
- Uniprot ID
- P08172
- Uniprot Name
- Muscarinic acetylcholine receptor M2
- Molecular Weight
- 51714.605 Da
References
- Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- Antagonist
- General Function
- Receptor activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM3
- Uniprot ID
- P20309
- Uniprot Name
- Muscarinic acetylcholine receptor M3
- Molecular Weight
- 66127.445 Da
References
- Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- Antagonist
- General Function
- Guanyl-nucleotide exchange factor activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM4
- Uniprot ID
- P08173
- Uniprot Name
- Muscarinic acetylcholine receptor M4
- Molecular Weight
- 53048.65 Da
References
- Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- Antagonist
- General Function
- Phosphatidylinositol phospholipase c activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM5
- Uniprot ID
- P08912
- Uniprot Name
- Muscarinic acetylcholine receptor M5
- Molecular Weight
- 60073.205 Da
References
- Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie D: Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol. 2000;49 Suppl 1:35S-42S. [PubMed:10771452]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Nakamura H, Nakasa H, Ishii I, Ariyoshi N, Igarashi T, Ohmori S, Kitada M: Effects of endogenous steroids on CYP3A4-mediated drug metabolism by human liver microsomes. Drug Metab Dispos. 2002 May;30(5):534-40. [PubMed:11950784]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A5
- Uniprot ID
- P20815
- Uniprot Name
- Cytochrome P450 3A5
- Molecular Weight
- 57108.065 Da
References
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A7
- Uniprot ID
- P24462
- Uniprot Name
- Cytochrome P450 3A7
- Molecular Weight
- 57525.03 Da
References
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Wilner KD, Demattos SB, Anziano RJ, Apseloff G, Gerber N: Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers. Br J Clin Pharmacol. 2000;49 Suppl 1:43S-47S. [PubMed:10771453]
Drug created on June 13, 2005 07:24 / Updated on July 13, 2018 00:57